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General Introduction 
 
 
 
 
 
 
 
 
 
2   Chapter I 
General introduction 
 
Dame Cicely Saunders founded the St Christopher’s hospice in London in 1967. 
This was the first centre in the world dedicated to offer patients and their families 
effective palliative pain and symptom control. Knowledge and new attitudes 
towards optimal palliative medicine and care were gradually developed there and 
progressively spread over Europe and over the world in the following 30 years. The 
awareness of the need for skills in palliation increased, especially in the nineties. As 
a consequence an increasing number of all kinds of manifestations of interest in this 
field of medicine has appeared in books, journals and meetings and let to the 
creation of dedicated services for palliative care.  
 
Palliative therapy and care are by definition the active, individually tailored, total 
care and the interdisciplinary management of the complaints and needs of the 
patients and their family, when the disease does not respond to curative treatment. 
In palliative care control of pain and other physical symptoms and of the associated 
psychological, social and spiritual problems is paramount. The primary goal is to 
try to achieve the best quality of life for patients and their families (1). Palliative 
patients must not be seen as medical failures for whom nothing more can be done. 
They need palliative care, which does not limit the care to just holding a patient’s 
hand, but treatment demanding as much skill and commitment as is normally 
brought into preventing, investigating and curing illness (2). This does not imply 
that palliation only starts when all curative measures have been exhausted. Many 
cancer patients will benefit and will have a better quality of life during their 
treatment if the principles of pain and symptom control of palliative care would be 
implemented much earlier in the course of the disease than at the turning point from 
cure to care.  
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1.1 Comprehensive symptom control during the course of the 
illness  
 
Good symptom control ensures a better quality of life for the patient during the 
course of any disease. This is especially true for cancer patients due to the wide 
variety of symptoms that can exist at the same time or consecutively in these 
patients. Cancer is a multi-symptomatic disease and pain is not the only factor that 
can disturb a patient’s quality of life. Symptoms are caused directly or indirectly by 
the illness, but in addition the side effects of the treatment (surgery, radiation 
therapy and systemic therapy) can also cause significant discomfort. Among the 
different symptoms, pain is not only the most feared by the patients, but also one of 
the most frequent symptoms (46-71%). Next to pain, fatigue (43-82%) is the most 
frequent symptom; the other relative frequent symptoms in cancer patients are 
weight loss, anorexia, constipation, nausea/vomiting and depression; they are less 
frequent (+20%) than pain and fatigue in the different studies (3). The same 
attention that is required to control pain must be directed towards managing other 
symptoms and discomforts in order to provide cancer patients an optimal quality of 
life at all stages of the disease (4). Palliative care principles and cancer pain 
management should be considered as part of a comprehensive cancer management 
(5). Pain occurs in about 50% of all patients treated for cancer. Pain relief measures 
and anti-cancer treatment have to go hand in hand. More than two thirds of patients 
with advanced disease experience pain; therefore the management of pain and other 
symptoms becomes the main aim of treatment in many cases (6). Of all symptoms 
occurring in advanced disease, pain is probably the most amenable to treatment. 
Yet, even in developed countries, over half of these patients do not receive an 
adequate level of analgesia, while experience in optimal palliative settings has 
proven that approximately 90-95% of these patients can be treated for their cancer 
pain if knowledge already available is used (7).  
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This unacceptable situation still exists because there is limited understanding of the 
nature of cancer pain in clinical oncological practice. There also is a failure to fully 
appreciate that pain is not only a physical sensation, but that psychological, social 
and spiritual factors contribute to pain experience. There still is a belief amongst 
many patients and caregivers that pain in cancer is inevitable and untreatable. 
Finally there also is reluctance to apply the well-established principles of the 
management of cancer pain, arising from inadequate education and confounded by 
irrational fears concerning the use of opioids (7).  
The suboptimal treatment of cancer pain has many causes, the most important of 
which probably is inadequate assessment (8). The discrepancy between the patient’s 
and the physician’s evaluation of the severity of the pain problem is a major 
predictor of inadequate pain relief (9). But some clinicians remain unwilling to 
prescribe sufficient doses of opioid pain relievers in part because they do not 
distinguish either morally or psychologically between actions performed with the 
intent to cause death and actions performed with the possibility of an adverse event 
resulting in death (10). US-clinicians to some extent are discouraged from 
prescribing or administering adequate doses of drugs to relieve symptoms of dying 
patients by the Pain Relief Promotion Act of 1999. This bill states that physicians 
may use controlled substances to alleviate pain or discomfort, even if the use of 
such substances may increase the risk of death. But the same bill forbids 
‘intentionally dispensing, distributing or administering’ a controlled substance for 
the purpose of causing death (11). Patients as well as doctors often have 
exaggerated fears of addiction and the side effects of narcotics. The second part of 
the bill still causes suboptimal treatment of patients who need very high doses of 
opioids at the end of life because physicians fear to be prosecuted. 
 
1.2 Cancer pain can and must be treated 
 
For many people, a diagnosis of cancer equals the expectation of a painful and 
debilitating illness, culminating in a distressing and perhaps meaningless death. The 
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process of dying, and in particular concern regarding uncontrolled pain, is often 
feared more than death itself. Prompt and effective relief of pain is a fundamental 
principle of palliative care that is enshrined in its very definition. The International 
Association for the Study of Pain already exists more than 20 years and we now 
have better understanding of pain and of the pharmacology of analgesics (12). The 
World Health Organization published a clinical alert three times since 1985 to 
optimize the relief of cancer pain (1, 5, and 13). The European Association of 
Palliative Care was founded in 1989 to collect all available knowledge and to 
provide guidelines to optimize palliative care, with a focus on cancer pain 
management and research in palliation (14). The American Pain Society reported in 
1992 that relief of pain in cancer patients is an ethical imperative and it is 
incumbent upon clinicians to maximize the knowledge, skill and diligence needed 
to perform this duty (15). 
The aim of treatment is to relieve the pain to the patient’s satisfaction, so that he or 
she can function effectively and eventually die free of pain. This implies that 
treatment has to be tailored to the individual, with drug treatment and anaesthetic, 
neurosurgical, psychological and behavioural approaches tailored to the individual 
patient’s need. 
 
1.3 Epidemiological data 
 
The number of cancer patients in the world is increasing, mainly because of the 
aging population and the increase in tobacco consumption (6).  At least 50-70% of 
all cancer patients will suffer pain some time during their disease.  In a large 
German study of terminally ill cancer patients only 9% of the patients required no 
systemic analgesics. Non opioid analgesics were effective in 5% and a combination 
of non-opioids and “weak” opioids in 16 % of the patients. In the remaining 70%, 
“strong” opioids alone or in combination with non-opioid analgesics were necessary 
to achieve adequate pain control. Additional co-analgesics and adjuvant drugs to 
treat special types of pain or other symptoms were prescribed in 90% of the patients 
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(16). In an updated German 10-year prospective study, 2118 patients were assessed 
over 140.478 treatment days (mean of 66 days/patient) during cancer pain relief and 
palliative care programs. Non-opioid analgesics (WHO step I) were used in 11%, 
weak opioids (WHO step II) in 31% and strong opioids (WHO step III) in 49% of 
treatment days. Analgesics were administered via enteral route on 82% and 
parenteral on 9% of treatment days. In the remaining days, either spinally applied 
opioids (2%) or other treatments (6%) were utilized. Fifty-six percent of the patients 
were treated with morphine. Over the whole treatment period, good pain relief was 
reported in 76%, satisfactory efficacy in 12% and inadequate control in 12% of the 
patients. Other frequent symptoms were neuropsychiatric disorders on 23% of days, 
nausea (23%), constipation (23%) and anorexia (20%) (17). In another study cancer 
pain also was the most frequent symptom in 67 of 126 patients (53%) receiving 
home care, and it could be effectively controlled with morphine; no patient returned 
to the hospital because of aggravation of pain (18). In the palliative care unit of the 
University Hospital of Leuven, 80% of the first 250 patients that died there used 
strong opioids for pain relief during their terminal phase of life. 
 
1.4 The concept of “Total Pain” 
 
The International Association for the Study of Pain provides the following 
definition: “Pain is an unpleasant sensory and emotional experience associated with 
actual or potential tissue damage, or described in terms of such damage. Pain is 
always subjective. Each individual learns the application of the word through 
experiences related to injury in early life. It is unquestionably a sensation in a part 
or parts of the body but it is also always unpleasant and therefore an emotional 
experience” (12). The above definition has two major strengths: firstly clinicians 
have to begin to learn to believe patients when they complain of pain and secondly, 
the definition recognizes the importance of the emotional factors in the appreciation 
of pain. In fact the pain perception threshold may be relatively constant for all 
individuals; the pain tolerance threshold is subject to considerable variation and 
General Introduction   7 
may be influenced by physical, emotional, social and spiritual factors (19). 
Sometimes is the threshold for physical pain so much influenced by existential 
concerns, social or spiritual components,  that these factors become  overwhelming 
in the total pain experience and that we probably better change the word ‘pain’ to 
existential, social or spiritual ‘suffering’ .  
For the clinician it is important to take the patient’s complaint of pain serious. 
Characteristics of the pain have to be defined by site, by onset, by quality and by 
intensity. This last aspect is mostly quantified with the visual analogue pain scale. 
Behavioural treatment methods have not been as widely implemented as 
pharmacological treatment methods in cancer pain. This is in contrast to treatment 
of non-malignant chronic pain where cognitive and behavioural programs are 
commonly applied (20). Cancer pain in most cases has a nociceptive basis. It 
however still is a multidimensional process, and thus potentially modifiable by non-
pharmacological factors. For this reason, pain management is an interdisciplinary 
activity and it’s no longer possible for one physician to competently cover all the 
different aspects of life that can influence pain perception. 
 
1.5 Acute and chronic pain 
 
The association of particular pain characteristics and physical signs with specific 
consequences of the underlying disease or its treatment defines pain syndromes. 
The evaluation of pain characteristics provides some of the essential data for 
syndrome identification. These pain characteristics are intensity, quality, 
distribution and temporal relationship. Knowledge of the pathophysiological 
processes can help to distinguish between nociceptive and neuropathic pain and is 
directly important for the management of pain.   Idiopathic pain, with no 
identifiable organic pathology or related to a psychiatric disorder, is uncommon in 
cancer populations.  
 
8   Chapter I 
Cancer pain is a chronic pain and has to be distinguished from acute pain in many 
aspects. Acute pain occurs in response to tissue injury or damage and the 
expectation is that, as healing occurs, the pain will lessen. The pain may even serve 
a useful function by forcing the patient to spare the damaged part, thereby 
enhancing the process of healing. Chronic pain occurs in a situation where it is  
unlikely that further healing will occur. In fact, because cancer is a dynamic 
process, more tissue damage is probable. The chronic pain as a consequence of 
advancing cancer serves no useful purpose. It is no longer a symptom of tissue 
injury or damage, but a hurting syndrome on its own. In advanced cancer, the 
symptoms are the disease (21).   
 
For all these reasons it is justified but also a challenge to treat cancer pain with 
proper assertivity and aggressivity. The goal of treating chronic cancer pain is not 
simply pain relief but also pain prevention. For sustained analgesia in most cases, 
around-the-clock dosing has to be instituted. Pain treatment on an “as needed basis” 
is inappropriate in most cases for two reasons. First of all, cancer patients are 
confronted with “chronic” pain that gradually will increase when the disease 
becomes more advanced. So the pain will return after a single administration of 
analgesics and there is no reason to let the patient suffer again before the next dose 
of analgesics is given. Secondly, the patient will try to postpone the intake of the 
following drug dose because in general he prefers to suffer some pain instead of 
taking analgesics on a regular and continuous basis. One of the challenges is to 
eradicate this misconception from the minds of patients, of families and especially 
of caregivers.  Supplemental rescue doses of analgesic drugs should be available to 
all patients for breakthrough and incidental pain due to progressive disease, activity 
or stress. As a guiding principle, the total maintenance dose plus the as-needed 
rescue medication in a specific time interval should become the regular dose during 
the next identical time period. The dose of the breakthrough pain medication is 1/12 
to 1/6 of the daily maintenance dose for pain intensities respectively below or above 
VAS-score 5 (14).  
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Pain prevention also is an appropriate goal in the management of acute moderate-
to-severe pain that is expected to last more than 24 hours. Resolution of the source 
of the acute pain should be anticipated with regular downward dose titration if the 
pain is well controlled without the need of additional analgesics. Therapy of acute 
pain that is not expected to last more than 24 hours can consist solely of treatment 
on an as-needed basis (22). 
 
1.6 Cancer pain can be multi-factorial and multi-focal 
 
Pain in cancer patients can be classified in four different groups (23): 
-Pain caused by the cancer itself; this is the most frequent reason (61%). The tumor 
can invade bones, soft and visceral tissues and peripheral nerves. 
-Pain caused by the treatment, like surgery, chemo- or radiotherapy. This pain can 
be more acute during or shortly after the therapy, or the pain can be chronic as a late 
effect of the treatment (5%) 
-Pain caused by general weakness, aches and stiffness associated with prolonged 
immobility and weakness (12%) 
-Finally there is pain that is unrelated to the cancer or its treatment; patients can also 
have other than cancer related pain due to degenerative, ischemic or inflammatory 
pathology (22%). 
 
In many patients, cancer pain can present at different sites at the same time. In one 
study, 4 or more separate sites were painful in 34% of the patients. This is of 
practical importance since the underlying cause of each of these pains may well be 
different, and consequently each may require a separate line of management (24). 
 
1.7 Palliative oncological treatments 
 
Surgery, radiotherapy, chemo- and hormonal therapy are very effective palliative 
treatments for pain and symptom control, in combination with analgesics as needed, 
as long as the anti-cancer treatment is effective.  
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Surgery is the most effective pain treatment option when a pathological fracture can 
be stabilized. Other good palliative surgical results are obtained by pleurodesis or 
by placement of derivative stomas on the colon and ureters or with small bowel 
bypass surgery. 
Radiotherapy is a very effective treatment for painful bone metastases, to resolve 
obstructions caused by tumor compression of blood or lymphatic vessels, of 
airways or the gastro-intestinal tract. Ulcerating tumors and hemorrhage in tumoral 
tissue can very effectively be irradiated to comfort the patient. Also neuropathic 
pain by nerve or plexus invasion or headache by intracranial hypertension 
secondary to brain metastases are frequently very good indications for palliative 
radiotherapy. 
Except in the case of lymphomas and small-cell lung cancers, chemotherapy is not a 
fast effective palliative treatment. However, in less urgent situations, chemo- and 
hormonal therapy can result in very long-lasting relief of pain and other symptoms, 
sometimes even for years, as is frequently seen in metastatic breast and prostate 
cancer. But there comes a time in the advanced cancer patient that anti-tumor 
treatment no longer remains a valid option, while before this turning point it 
frequently was the first choice of treatment for pain and symptom control. 
 
After that turning point, drug treatment becomes the mainstay of cancer pain 
management. But if we focus all our efforts on achieving control of pain, without 
regard to all other factors like anxiety and depression, it is highly unlikely that we 
will achieve an optimal level of success (25). The effective treatment of chronic 
pain needs a multidisciplinary approach. It is not just the application of the 
necessary skills involved; success also requires a relationship, based on trust, 
between the patient and the professional caregivers so that emotional and 
psychological aspects also can be considered (26). 
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1.8 Pain assessment and measurements 
 
A physical examination, including a neurological examination, is a necessary part 
of the initial pain assessment. The physical examination should attempt to identify 
the underlying causes of the pain problem, clarify the extent of the underlying 
disease and discern the relation of the pain complaint to the disease. Expert 
assistance from physicians in other disciplines, nurses, social workers, or others 
may also be necessary to evaluate related physical or psychosocial problems 
identified during the initial assessment. Pain must be managed during that process 
to improve compliance and reduce the distress associated with procedures. No 
patient should be inadequately evaluated because of poorly controlled pain (27). 
Careful review of the laboratory and imaging studies can provide important 
information about the cause of the pain and the extent of the underlying disease. 
Additional investigations are often needed to clarify uncertainties if appropriate to 
the patient’s general status and the overall goals of care (27). In a comprehensive 
pain assessment in the management of patients with cancer, a pain consultant at 
Memorial-Sloan-Kettering Cancer Center identified a previously undiagnosed 
etiology for the pain in 64% of 276 consecutive consultations. The most common 
diagnosis was metastatic tumor and new neurological diagnoses were established in 
36% of the patients (28). Besides a careful history and clinical examination there 
was a need for 264 radiographic and 16 laboratory studies, 6 lumbar punctures and 
1 electromyography. 
 
It is essential to establish the cause or the causes of the pain before planning pain 
treatment. A detailed pain assessment as just mentioned will gather the necessary 
information to make the correct clinical diagnosis. This diagnosis has to be 
explained to both the patient and the family. They have to understand what the aims 
of the treatment are and what they can expect or not expect.  
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Regular evaluation of both the therapeutic effect on pain and the intensity of the 
side effects are mandatory for all patients who suffer from chronic pain. To evaluate 
the result of pain treatment, there is a need for a reliable and accurate way of pain 
measurement. The greatest single problem may be inadequate pain assessment by 
the patient and the caregivers. Informing caregivers and patients that their 
cooperation in pain treatment is essential can rectify this deficiency.  
The tool used most frequently is the numerical rating scale (NRS); it is a one-
dimensional scale (29) that consists of a horizontal or vertical line evenly anchored 
or divided into 10 segments numbered consecutively between 0 and 10. Patients 
may be instructed that 0 represents “total absence of pain” and 10 denotes the “most 
severe pain they can imagine”. The patient is instructed to simply mark the number 
that best describes the level of pain he is experiencing at a given point in time.  
Technically, for such a scale to be truly visual analogue in character (visual 
analogue scale or VAS), it should consist of only a line with anchors at both ends 
and none in-between. This is the simplest tool of pain measurement that just 
quantifies the pain intensity, but lacks some qualitative information about the pain 
(29).  
A modified visual-scoring system for use with children substitutes a continuum of 
smiling to crying faces for numbers (30). A verbal rating scale (VRS) with 
indications “no, mild, moderate, severe, intolerable” proves easier to apply and may 
be more reliable in the presence of cognitive impairment (31).  
A more comprehensive scoring system is the Mc. Gill Pain Questionnaire (MPQ) 
(32) that is widely recognized as a valid and reliable instrument to measure pain. 
It’s a pen and paper instrument that, in addition to other components, instructs the 
patients to make relevant selections from a list of 78 adjectives used to describe 
pain. The selected adjectives help to evaluate the extent to which pain is 
predominantly sensory or affective (33). Another feature of the MPQ is a schematic 
representation of the body that is shaded by the patient to indicate where pain is 
located. This component can be modified to provide additional information by 
instructing the patients to inscribe a numeric value that signifies regional pain 
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intensity in the shading areas. The MPQ is also relevant to assess the patient’s 
psychological status, although there exist other sophisticated questionnaires 
(Wisconsin Brief Pain Questionnaire measures pain and does a careful 
psychometric analysis, the Varni Thompson pediatric brain questionnaire has been 
formulated in separate versions for children, adolescents and parents) to assess 
psychological factors that often have an important bearing on pain, such as the 
patient’s personality, the presence of depression or anxiety, hypochondria, 
preoccupation with body image, etc.(34). While a comprehensive battery of 
psychological testing is usually considered to be an appropriate component of the 
assessment of the patient with chronic non-malignant pain, it is essential that testing 
of the cancer pain patient be brief and not excessively demanding. Several practical 
and useful tools have been introduced that specifically target patients with cancer 
pain and that possess these attributes. These include the Wisconsin Brief Pain 
Inventory and the Memorial Brief Pain Assessment Card (35). The latter is a 
simple, efficient and valid assessment instrument that can provide rapid evaluation, 
in clinical settings, of the major aspects of pain experienced by cancer patients. It 
consists of a two-sided card with 4 scales to measure the intensity of pain, the pain 
relief, mood and a set of descriptive adjectives. 
Patients have to be taught how to use pain measurement tools and how to rate and 
to register their pain scores. This has to be discussed daily at the start of the pain 
therapy and, when the analgesic dose is stabilized with good pain relief, a weekly 
discussion between patient and physician seems sufficient (36). 
 
1.9 Analgesic drugs 
 
When anti-tumor treatment no longer is possible, symptomatic pain relief becomes 
the mainstay of treatment. The analgesic drugs are chosen according the WHO 
analgesic ladder for cancer pain management (6).  
The sequential use of the drugs according to the WHO ladder allows prescription 
adapted according to respectively mild (VAS-score 1-3), moderate (VAS-score 4-6) 
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and severe (VAS-score 7-10) pain. Only one drug belonging to steps II and III 
should be used at the same time; adjuvant drugs should be given for specific 
indications. The non-opioids of step I (paracetamol, salicylates and the non-
steroidal anti-inflammatory drugs) are used for mild pain. These three different non-
narcotic analgesics can be used separately for mild pain or the NSAID’s can be 
combined with paracetamol or salicylates to be more effective. 
Patients with moderate pain should be treated with weak opioids (WHO step II), 
where codeine is the reference drug. A combination with two or more analgesics 
belonging to step II (tramadol, paracetamol-codeine, tilidine, propoxifene and 
buprenorphine) is never indicated. When a step II drug ceases to be effective at its 
maximum dose, it is recommended not to switch to another drug of similar efficacy 
but to prescribe a drug that is definitely stronger (step III). 
Morphine is the reference drug in step III but also fentanyl and methadone belong 
to step III. The analgesic drugs of step II have to be stopped and are replaced by 
strong opioids, starting with the appropriate dose of long-acting equivalent of 60mg 
oral morphine per 24h. Breakthrough medication with short acting morphine needs 
to be available for all patients treated with strong opioids.  Sometimes a step I 
analgesic drug is added to the therapy with weak or strong opioids to obtain a more 
potent analgesic effect. A typical indication is the combination with paracetamol or 
NSAID’s for bone pain or pain to which some inflammation contributes. Major 
indications for ketorolac are pain associated with trauma to bones and muscles, but 
also cancer related pain, in which a “saving effect” on simultaneously employed 
opioids can be achieved (37). Due to its long half-life, methadone is not a preferred 
painkiller in cancer; it can be difficult to adequately adapt the dose while the pain 
score is increasing. Secondly there is a risk of delayed toxicity as plasma levels of 
methadone gradually rise due to dose increments or a major organ failure which 
frequently happens in terminal patients. 
Fentanyl is applicable as a transdermal therapeutic system (TTS-fentanyl) that is as 
effective as morphine but has a more favorable profile of side effects, especially at 
very high doses, for patients of all ages. 
General Introduction   15 
All the analgesics of step I and II, except buprenorphine, have a ceiling effect. This 
implies that no better analgesia is obtained by increasing the dose above the advised 
maximum dose, only the side effects increase. Morphine, methadone and fentanyl 
however, do not have such a ceiling effect. There is a linear relationship between 
the plasma concentration of morphine and increasing doses. An analgesic effect is 
obtained with higher doses for pain not controlled with the lower doses.  
The fear of physicians, nurses, patients and family to induce addiction or tolerance 
by using strong opioids is partly responsible for the insufficient use of opioid drugs. 
But available studies indicate that in cancer patients iatrogenic addiction is quite 
rare (less than 1%) and the risk of a major tolerance is very small (38). In general, 
families are more anxious about morphine than the patients themselves. In a study 
of 539 patients one addicted patient (0, 18%) was found, who however had begun 
drug use long before pain treatment was required (39). 
The use of lower doses of morphine is possible when concomitant non-opioids and 
specific co-analgesics are used. The lower doses result in a lower incidence of side 
effects; in a long-term survey, constipation and nausea/vomiting were the most 
common side effects of morphine while tolerance and addiction did not appear (40). 
The co-analgesics can potentiate the morphine analgesia by causing an increased 
bioavailability of the opioids, but also by an intrinsic analgesic effect. 
Corticosteroids have an anti-inflammatory action and decrease edema, so they can 
decrease pain due to intracranial hypertension or decrease the tension on the liver 
capsule in an enlarged metastatic liver. The use of an antidepressant or 
anticonvulsant is suitable when a neurogenic pain component is present. The use of 
antidepressants is indicated when a deafferentiation pain is present or when there is 
a concomitant depressive illness (41). 
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1.10 Analgesic drug administration in cancer pain 
 
1.10.1 Oral administration 
 
Both the World Health Organization and the European Association for Palliative 
Care advise to administer the analgesics orally for chronic cancer pain (1, 14). This 
is an inexpensive and yet effective method for relieving cancer pain in more than 
70% of the patients. In this way the patients are independent from their caregivers. 
A double dummy, crossover study on 52 cancer patients compared controlled 
release morphine suspension and controlled release morphine tablets. There was no 
statistically significant difference in severity of pain assessed on a visual analogue 
scale, the need for rescue doses of immediate-release morphine, treatment 
preference by the patients, and indices of quality of life (activity, mood, and sleep). 
This study showed that, when prescribed in the same doses, controlled release 
suspension and tablets have similar efficacy and adverse effects, as well as the same 
duration of action (42). Although oral administration of analgesics is standard 
clinical practice, a significant proportion of patients cannot be treated in this way. It 
has been estimated that more than 50% of patients with advanced cancer will 
eventually be unable to tolerate oral morphine (43) because of problems with 
swallowing, persistent nausea and vomiting, bowel obstruction, intolerance to oral 
opioids, incident pain or poor compliance to an oral regimen (44). 
 
In a study of 100 patients, the majority required at least 2 administration routes and 
1/3 of the patients required 3 routes of administration (45). The oral route is usually 
preferred, because it is simpler, easier to use, and less expensive than parenteral 
therapy (46, 47). There is limited bioavailability of some opioids, the alterations in 
metabolism that are associated with presystemic elimination (liver first pass effect), 
the slightly slower onset of analgesia and the delayed peak time all support the need 
for other routes of administration that may avoid these disadvantages. Subcutaneous 
or intravenous administration of morphine or hydromorphone is preferable to 
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transdermal administration of fentanyl in patients who are unable to take oral 
medication for 24 or 48 hours or for a longer time because of severe nausea, 
vomiting or gastro-intestinal disorders. Also for patients with frequent episodes of 
incident pain or patients with acute, severe pain who require rapid onset of 
analgesia, SC or IV injections or infusions are preferred over the other 
administration routes (22, 48). 
 
1.10.2 Transdermal administration 
 
Once equilibrium is reached, the transdermal fentanyl system maintains serum 
concentrations of fentanyl similar to those found with constant intravenous infusion. 
The analgesic effect of transdermal fentanyl is proven. There are a number of 
potential benefits to this administration route. The system is more convenient for 
the patient and the caregivers than the parenteral, rectal or spinal routes, and the 
overall costs are much lower (49). It can be used in patients who are unable to 
tolerate oral morphine, and are too sick or confused to be taught how to use a 
patient-controlled infusion pump. When compared with the oral administration, it is 
also potentially advantageous, largely due to the 3-day dosing. This reduces staff 
time in administering the drug and may also improve patient compliance. It may be 
suitable for patients who can tolerate oral opioids, and appears to be a highly 
beneficial alternative for those who cannot (50). The patient is more independent 
from the caregiver and there no longer is a reason for clock watching. Possible 
disadvantages of transdermal administration include a long latency of onset after 
application and the continued absorption from a subcutaneous depot after the patch 
is removed, resulting in a slow decline in plasma concentration after removal. 
During the dose titration and stabilization period, patients may require other opioid 
analgesics, and these may also be required for breakthrough pain once patients are 
stabilized. The transdermal application system is most suited for patients who have 
relatively stable levels of pain. Significant increases in TTS-fentanyl (Transdermal 
Therapeutic System) were necessary during weeks 1 through 4 to maintain pain 
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control. Fifty-nine percent of the patients needed one or more dose increases (50). 
Patients and physicians reported satisfaction with the transdermal fentanyl therapy, 
95% of the patients prefer to continue the transdermal fentanyl therapy at the end of 
the study, due to better performance in comparison to oral morphine (51). 
Transdermal fentanyl probably is not a good analgesic drug for patients with 
generalized edema, for those who are medically unstable, who need analgesic drug 
titration, who need frequent dose changing, or when frequent breakthrough pain is 
present. 
 
1.10.3 Parenteral  administration 
 
Subcutaneous, intramuscular or intravenous injections of morphine at regular 
intervals can control moderate and severe cancer pain in most patients (52) and is 
common practice when oral medication cannot be taken. However injections need 
to be repeated every 4 hours. This is undesirable because it becomes painful for the 
patient, time consuming for the nursing staff, and difficult to maintain in the home 
setting. The injections are often “complicated” by the occurrence of a prominent 
“bolus” effect. Some patients experience marked toxicity at high peak plasma 
levels, with nausea, vomiting or somnolence, while injections offer no 
pharmacokinetic advantage. For all these reasons regular injections are not 
recommended (53).  
Repeated bolus doses can be accomplished without frequent skin punctures through 
the use of an indwelling subcutaneous (S.C.) infusion device. The appropriate 
selection of the right opioid drug and a continuous route of administration were 
associated with improvement in pain relief and a lower prevalence of cognitive 
impairment, hallucinations, nausea, vomiting and myoclonus among patients who 
were discharged from the hospital (54). Already since 15 years studies have proven 
that continuous intravenous infusions (C.I.V.I.) of analgesics are safe and effective 
to treat both postoperative and cancer pain (55). Continuous subcutaneous infusion 
(C.S.C.I.) was already in 1988 experienced as effective and comfortable that after 
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48 h. use even 94% of 108 patients preferred the subcutaneous infusion to the 
continuous intravenous or repeated intramuscular route. Forty-seven percent (n = 
33) of the patients (n = 70/108) treated with a portable pump were discharged home 
(56).  
Ventafridda treated in the same era 40 patients with a syringe driver with pain relief 
as good as intermittent injections, while less nausea was seen with continuous S.C. 
infusion (57).  
The Pharmacia-5800 pump allowed the patient to give himself a bolus during the 
continuous infusion and this improved pain control in all patients (n = 18) in the 
study of Kerr; 5/18 patients could die at home with the support of their family (58) 
In the first years of the use of C.S.C.I., there was some concern about the possible 
irregular absorption of the subcutaneously injected analgesics. Waldmann et al. 
measured blood levels of morphine in 9 patients receiving C.S.C.I. and in 4 patients 
receiving C.I.V.I. They found no difference between C.I.V.I. and C.S.C.I. (59). 
Peak plasma levels are achieved within 15-20 minutes of intramuscular and 
subcutaneous and within 30-90 minutes after oral administration. Peak levels after 
oral administration are much lower than after parenteral administration, since oral 
morphine undergoes extensive first-pass metabolism in the liver (59). 
After starting C.S.C.I. of strong opioids, the site of infusion has to be checked daily 
and the infusion place should not be changed until signs or symptoms of local 
intolerance develop (pain, redness, swelling, leakage). The mean duration of 
infusion at a single site was 7.3+5.2 days (range 1-29) for 119 sites in 45 patients 
(60). The most frequent signs of local toxicity were redness and swelling without 
serious local complications; these results suggest a weekly change of infusion site 
to be appropriate. 
 
Morphine is the drug of choice when parenteral strong opioids are necessary to 
relieve severe cancer pain. When unacceptable side effects occur, morphine can be 
replaced by a continuous subcutaneous fentanyl or sufentanil infusion. Both can 
achieve good analgesia with a low rate of adverse side effects (60). Patients, who 
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cannot swallow, with severe nausea or vomiting, with malabsorption, are candidates 
for this treatment modality. Patients who need extremely high doses and who have 
some discomfort swallowing pills, or who have decreased consciousness due to the 
high dose, can also switch to C.S.C.I.  Patients who experience adverse effects from 
the peak serum levels when opioids are given intermittently can benefit from a 
continuous infusion. Renal failure is one of the rare contra-indications for C.S.C.I. 
because of the risk of accumulation of morphine that will result in excessive 
sedation and confusion for several hours or even days. Therefore, in addition to 
breakthrough pain, the presence of renal failure is the only other reason to give 
analgesics as needed. The programmable computerized infusion pump was found to 
be more cost-effective than the disposable infusion device after a break-even point 
at 8 months (61). 
 
Because of the simplicity, technical advantages, and cost effectiveness of 
continuous subcutaneous opioid infusion into the chest wall or the trunk, 
intravenous opioid infusion for the management of severe cancer pain should be 
abandoned. Drugs given by the subcutaneous route have a reliable absorption and 
this method has been demonstrated to be safe and effective in cancer pain 
management. On this basis, it should be considered the standard alternative route 
against which all newer routes of administration should be tested (62). 
Many oncological patients previously had chemotherapy via implanted central 
venous catheters systems. These venous access devices can be used to administer 
drugs for symptom control like analgesics, anti-emetics or sedatives. However 
parenteral administration can also cause some discomfort to patients, in some cases 
it can result in sepsis (IV) or tissue irritation (SC). Although cancer pain 
management is mainly managed intravenously in hospitals, there are little scientific 
data available in recent literature concerning this administration mode. Due to the 
growing use of venous access devices to administer cytostatics, patient controlled 
analgesia with a portable pump linked to these devices has becomes feasible and 
allows patients to return home without changing the administration route. One of 
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the advantages of the intravenous route is the greater possibility of mixing different 
drugs while there are sometimes limits to the volume of these mixtures that can be 
given in a continuous subcutaneous infusion. A continuous drip infusion of 
morphine progressively increases the plasma concentration of morphine in parallel 
with increase in morphine dose if the patient has no pleural effusion, ascites or 
edema. In contrast, in patients with pleural effusion, ascites, or edema, the plasma 
morphine concentration was about half of that observed in patients who have a 
normal distribution volume. The rapid development of pleural effusion or ascites 
lowers the blood level of morphine (63). 
Morphine sulphate continuous released suppositories (MS-CRS), administered 
every 12 hours, provide analgesia comparable to S.C. morphine and represent a 
reliable, non-invasive alternative method of pain control for patients unable to take 
oral morphine. This option is equally effective and simpler to institute for patients 
with a short life expectancy (64). 
 
1.10.4 Spinal and intraventricular administration  
 
Spinal administration of opioids, alone or in combination with local anesthetics, 
should be reserved for patients in whom systemic analgesic therapy is unacceptably 
or unmanageably toxic (22) or if there is little or no pain relief with increasing 
dosages of systemic strong opioids. 
 
In some very selected cases, intraventricular morphine administration is indicated to 
alleviate intractable cancer pain, especially for patients with pain from head and 
neck cancers or from tumors invading the brachial plexus (65).  
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1.10.5 Conclusion on administration of analgesics 
 
Advances in the management of cancer pain with opioids resulted from the 
development of slow- and sustained release tablets as well as novel alternative 
routes of drug administration (transdermal, buccal, transmucosal, subcutaneous, 
epidural and intrathecal) and drug delivery with intermittent and continuous patient 
controlled analgesia pumps. These different approaches make it possible to 
maximize the individualization of opioid therapy to obtain optimal analgesia while 
minimizing side effects, and provide convenient methods of drug administration 
(48). 
 
Controversy continues to exist over the relative merits of the various standard and 
novel routes of administration and the indications for their use in the treatment of 
cancer pain. New routes of administration have become fashionable but often lack 
kinetic and clinical logic (66). Conflicting views about the usefulness and efficacy 
of these methods have resulted in considerable variations in practice, even among 
specialists in palliative care and pain management (26). The European Association 
for Palliative Care therefore set up a working group of experts to formulate 
recommendations for the use of morphine for cancer pain based on the available 
evidence (14). The oral route is the preferred one for administration of strong 
opioids, followed by the transdermal and subcutaneous routes. 
All currently used approaches have demonstrated good analgesic efficacy and 
controllable adverse effects and have been instrumental in improving the quality of 
life when adequate analgesia has been achieved. There was and still is controversy 
as to whether the continuous infusion of strong opioids leads to more rapid 
development of tolerance than other routes (62, 63). Firm data to prove this are 
lacking and extensive clinical experience suggests that >90% of the patients who 
require an escalation in opioid dose to manage increasing pain have disease 
progression. 
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The choice of the route of morphine administration should mainly be guided by the 
needs of each individual patient. The location of the treatment will influence the 
choice of the analgesic. In the majority of cases, oral opioids are still the first choice 
but if the patient is no longer able to tolerate oral administration, for whatever 
reason, a number of factors must be considered and the availability of expertise and 
equipment is one factor which should not be neglected (67).  
 
1.11 Hospital and home care 
 
After the previous paragraphs it is clear that patients can be effectively treated for 
cancer pain in every health care setting thanks to the numerous analgesics and the 
different administration routes. Research has proven that symptom control at home 
can be as good as or even better than in the hospital. When physical, emotional and 
social parameters are considered, skilled care in the patient’s own home is seen to 
be more effective. By far the majority of incurable cancer patients (about 70%) 
prefer to spend their remaining days in the comfort of their own home. At the 
beginning of the eighties many palliative caregivers, supported by many patients 
and their families, strongly believed that home is the preferred place of care for 
most terminal cancer patients (68). At the end of the nineties more and more 
experienced home care professionals became also available in Belgium to help 
families ensure that the dying process at home be as free of pain and as peaceful as 
possible. Nevertheless, it may happen that palliative care at home is no longer 
feasible for physical, social, economic or psychological reasons. At that moment the 
incurable patient himself or his family will, in consensus with his caregivers, opt for 
hospital admission for treatment, for temporary care, or to die. The relative weight 
of the different reasons why these patients enter hospital, how much time they 
spend there and how many of them can return home is not well studied.  Can the 
hospital better offer these patients some effective treatment? 
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1.12 Strong opioids and elderly cancer patients  
 
Many physicians, nurses and family members believe in clinical practice that 
elderly patients are at increased risk for opioid-induced side effects.  Morphine 
therapy is therefore in these patients frequently postponed or given in too low 
dosage. Research in cancer pain treatment has given limited attention to the 
advanced age group. Because of the aging population, their number is progressively 
growing and they have a relatively high prevalence of cancer. We lack good 
scientific data for elderly patients concerning the real clinical efficacy in pain 
control, the tolerability of analgesic drugs and the handling of the side effects. 
Clinical investigation of these issues is therefore highly desirable since the number 
of elderly cancer patients will remain increasing in the next decades (6).  
  
1.13 Strong opioids and tolerance 
 
 
In 1986 the W.H.O. published the report “Cancer pain relief” to optimize cancer 
pain treatment. The report stressed that the greatest improvements in the quality of 
life of cancer patients could be obtained by applying the existing knowledge of pain 
and symptom control (13). By following these WHO guidelines, some investigators 
reported a very acceptable pain relief in 70-80% of patients (16, 17). Still seventeen 
years later, cancer pain treatment is far from optimal in the Belgian and Western 
health care systems. There are many reasons why physicians and cancer patients do 
not use strong opioids according to the internationally validated guidelines. 
First of all there still is a worldwide lack of knowledge about pain pathophysiology, 
about the different analgesics and their pharmacokinetics. Thereby health caregivers 
did not really modify their attitudes in spite of the existing validated guidelines of 
the WHO.  
Secondly there are the morphine myths. They suggest that strong opioids induce 
physical tolerance, depress the respiration, cause physical addiction and trouble the 
consciousness of the patients. All these myths restricted the use of strong opioids 
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for many decades, while strong scientific support for these myths was and is not 
present.  On the other hand, I couldn’t find published data about the percentage of 
patients with induction of tolerance, respiratory depression and confusion in cancer 
patients when they are treated according to the international guidelines.  
Thirdly physicians have to give their patients a definite role in their own pain 
therapy with more freedom for the patients to adapt doses and administration of 
breakthrough medication (69).  
Finally patients and caregivers are scared by the local legal regulations. The laws in 
many states discourage the optimal use of opioids via the sometimes difficult 
prescription policy (the limited dose per prescription, the administrative burden and 
controls) (70). A study found that nearly half the patients (48.8%) described their 
general practitioner as  suspicious or skeptical towards opioid therapy (71). 
 
Some patient organizations declared at the end of the 20th century that the 
time is ripe for professional accountability, including actions by medical 
disciplinary boards, when pain treatment is not adequately offered in the 
health care systems. I still agree in 2003 with the statement of Connolly in 
1987: “What is needed now is not a stunning new understanding of pain 
pharmacology, but the consistent and rational application of what we already 
know. History will judge us harshly if we continue to fail to meet even this 
modest goal” (72). 
 
We do not need other or better guidelines for opioids in cancer pain 
treatment and we cannot change the laws in many countries in a few years.  
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We have to optimize the physicians’ and nurses’ attitudes in cancer pain treatment 
by giving better pain treatment education, by giving practical training in pain 
therapy, by learning to use outcome measurements both by patients and caregivers 
and by looking for correct scientific data to assess the importance of the morphine 
myths. 
 
1.14 Refractory symptoms in terminal palliative patients 
 
 
Palliative care received some attention in West-European medical practice since 
+1980 and progressively became available for many palliative patients in the last 
two decades. Even the most optimal pain treatment cannot always relieve all pain 
and suffering. These are the so-called “intractable” or “refractory” symptoms to 
standard palliative treatments. Refractory symptoms have to be differentiated from 
‘difficult to treat symptoms’. A difficult to treat symptom is refractory when after 
implementing the advice of several clinical experts the symptoms of the patient still 
cannot be relieved. A refractory symptom cannot be adequately controlled despite 
aggressive efforts to identify a tolerable therapy that does not compromise 
consciousness (73). Refractory symptoms are sometimes so overwhelming for 
patients, family and caregivers that they preclude a dignified terminal phase or 
dying process. 
Palliative sedation can sometimes be indicated for these patients as an ultimate tool 
to control otherwise intractable symptoms in suffering patients. This is a 
controversial ethical topic since many years. Some authors have suggested that 
physicians use sedation to hasten death (74). Other authors have wondered why to 
sedate the patient if many patients and family members could ethically accept 
euthanasia when terminally ill patients have to suffer (75). The ethical debate 
moreover is intensified by the suggestion that sedation could be used as “slow 
euthanasia” (76). 
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1.15 Questions to be studied 
 
In chapter II we analyze the data of the palliative cancer patients who were admitted 
to the hospital through an emergency procedure and for whom pain was the only or 
one of the dominant complaints. We evaluated the reasons for hospitalization, what 
the hospital could offer and what the outcome was for the patients. 
 
Chapter III analyses the tolerance to TTS-fentanyl and rescue doses of morphine. 
The convenience for the patients, with a special focus on the elderly patients, and 
their compliance to the patches are analyzed. 
 
Chapter IV studies the increase in opioid dose in function of time. The consumption 
of strong opioids is measured in a large number of patients treated for at least 3 
months and at most 24 months. The importance of opioid tolerance in cancer pain 
treatment over a two-year period will be assessed. 
 
Chapter V presents our experience with palliative sedation. How many symptoms 
remain refractory to modern effective pain treatment? Can palliative sedation 
relieve pain and suffering if pain treatment and other appropriate measurements fail 
and what are the ethical implications of palliative sedation? Is palliative sedation a 
true palliative tool or is it just a concealed method of euthanasia?  
 
On the basis of the results obtained, we finally formulate some provisional 
conclusions with perspectives for future clinical research.
  
  
 
 
 
 
 
Chapter II: 
 
Emergency hospital admission for 
pain in palliative patients. 
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2.1 Patients and methods 
 
All palliative patients who entered the oncological ward of the Leuven University 
Hospital as emergencies were prospectively registered during a 3-month period. 
The different complaints and symptoms of the patients were prospectively 
recorded.  The tumor type, all diagnostic, supportive and therapeutic measures 
taken in the hospital were registered.  The length of the hospital stay was 
measured in relation to the different diagnostic and therapeutic activities 
performed and the destination upon discharge was recorded. 
 
2.2 Analysis 
 
This is a descriptive correlational retrospective study. Palliative cancer patients 
were at random prospectively registered during 3 consecutive months entering 
the hospital in emergency for pain. The absolute patient numbers are reported. 
The percentages of different groups of patients are referred to the total group of 
67 patients (= 100%). The medians were calculated because the data were non 
parametric. The Fisher’s Exact Test was used to calculate the differences between 
patient groups. The difference in hospitalization duration for oncological treated 
and patients that were just cared for was calculated with the t-test. 
 
2.3 Results 
  
Sixty-seven (54%) out of the 124 admitted palliative patients had pain as either 
the only or one of the main reasons for emergency hospital admission.  These 67 
patients with pain are the focus of this study. 
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2.3.1 Pattern of entrance into the hospital 
 
Thirty-one patients (46%) were admitted via the emergency ward and 16 (24%) 
were sent from home immediately to the oncological ward. Ten (15%) patients 
were admitted via the hospital’s outpatient department, 5 patients (7%) came via 
the day-care hospital and 5 patients (7%) via the radiotherapy department.  
In patients coming straight from home (n = 48/67), there was equal distribution 
between those who decided autonomously (n = 23) to enter the hospital and those 
who were referred by the general practitioner (n = 25).  For all patients in whom 
the general practitioner took the decision to request emergency admission 
(25/25), a referral letter was available. Seventeen out of 31 emergency ward 
patients and 11/16 patients coming directly from home had a written referral 
(=60%) from their general practitioner.  The oncologists from inside the hospital 
(outpatient department and day-care hospital) sent in fifteen patients, and for 4 
patients it was not clear who finally decided the admission.   
For 44/67 patients (66%) a referral letter was available. The aim of the 
hospitalization by emergency was briefly mentioned in the referral letters while 
the respective analgesics and their doses were very rarely reported. Figure 1 
shows that 51 (67%) patients entered during the working hours in the week and 
that only 2/67 patients in this study were admitted by emergency to the hospital 
during the weekend.  A high number of emergency admissions were seen on 
Monday (27%), there were less on Tuesday (21%) and a steady state was reached 
from Wednesday (15%) to Friday (18%). 
 
2.3.2 Demographics 
 
The demographic data are presented in Table 1. There is a clear female/male ratio 
of 2.2. This is mainly caused by the large number of breast cancers (n = 24), 
which constitute the most important group of patients in the Oncology 
Department. Lung cancer is the second most frequent malignancy in this patient 
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group.  All the other tumor types (head & neck, gastro-intestinal tract, urological, 
gynecological cancer, lymphoma, sarcoma and brain tumor) are nearly equally 
represented. 
 
Figure 1: Distribution of the number of patients admitted in emergency to the 
hospital in function of day and hour of hospital entry. 
 
 
Table 1: Demographic data 
Male          N= 21 
Female      N= 46 
Age:   median = 61.66 y 
           median = 54.6 y 
Age:   range 42-88 y 
           range 19-86 y 
Primary cancer site      N 
Breast                         24 
Lung                           11 
Head & neck                5 
Gastro-intest. tract     5 
Urological                  5 
Lymphoma        5 
Sarcoma             4 
Brain                  3 
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2.3.3 Clinical symptoms of the patients 
 
Pain was the inclusion criterium for this study and thus was present in all 67 
patients. Pain was the only symptom on the day of admission in 17/67 (25%) 
patients.  The other symptoms and complaints (Table 2) were never the only 
reason for admission by emergency; there always was a combination of pain with 
1 (n = 24/67 or 36%), 2 (n = 22/67 or 33%) or maximum 3 (n = 4/67 or 6%) other 
symptoms or complaints.   
Besides pain, the most frequent other symptoms or complaints were: cachexia (n 
= 20/67), dispose (n = 12/67), need for increased physical care (n = 15/67), fever     
(n = 9/67), nausea/vomiting (n = 8/67), gastro-intestinal obstruction or diarrhea (n 
= 5/67), social reasons (n = 4/67) and vena cava superior syndrome, hemorrhage 
and anxiety (n= 2/67).  The remaining symptoms were reported in only one 
patient (ascites, confusion, edema in legs, anemia, neurological deficit and 
phlegmonia). 
 
Table 2: Symptoms and complaints causing hospital admission by emergency. 
 
Symptoms & complaints             N           Symptoms  & complaints                  N           
Pain                                              67 
Cachexia                                      20 
Dyspnoea                                     12      
Additional care needed                15 
Fever                                             9 
Nausea & vomiting                       8 
GI-obstruction /diarrhoea             5 
Social reason                                4 
Vena cava superior syndrome            2 
Haemorrhage                                      2 
Anxiety                                               2 
Ascites                                                1 
Confusion                                           1 
Oedema in the legs                             1 
Anaemia                                             1 
Neurological deficits                          1 
Phlegmonia                                         1 
 
34   Chapter II 
2.3.4 Reason for hospital admission and hospital activities 
 
The patients were referred, or entered the hospital for additional nursing and 
medical care (N = 15; 22%), for diagnostic work up (N = 41; 61%) or for 
treatment (N = 59; 88%).  Table 3 shows that the referrals were very realistic and 
correctly implemented by the hospital, because what really was done is exactly 
what the patients were referred for: 21% of the patients only received care, 68% 
underwent diagnostic procedures and 92% received some form of therapy. 
 
Table 3: Reasons for referral and what effectively is done in the hospital 
 
Reason for referral What effectively is done?  
        N        %        N           % 
Nursing care 
Diagnostic procedures 
Therapy 
        15 
        41 
        59 
       22 
       61 
       88 
       14 
       46 
       62 
         21 
         68 
         92 
 
2.3.5 Treatments done in hospital 
 
All treatments applied in hospital are summarized in table 4. Analgesic treatment 
was adapted or started in 39/67 (58%) patients.  This group can be divided into 
two groups in which 25/39 (64%) patients received “hospital specific treatments” 
and the other 14/39 (36%) patients received non-hospital specific treatments. The 
hospital specific treatments for 25/39 patients were specialized or permanent 
need for nursing (n=9), radiation therapy (n=8), chemotherapy (n = 7), 
disphosphonates, referral to surgeon, blood transfusion, parenteral feeding, 
ascites puncture, thoracic drainage, a Port-à-Cath implantation.  
There were 21 non-hospital specific treatments done in the 14/39 patients and for 
5/25 patients from the first hospital specific treatment group: rectal clysma, 
placement of an urinary catheter (n=2), administration of antibiotics (n=3) or 
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corticosteroids (n=3), adaptation of medical pain therapy (n=9), administration of 
anti-emetics or oxygen and delivery of wound care (each n=1).  
Although 14/39 patients didn’t really need the hospital infrastructure for their 
treatment, 11/14 of these patients had some diagnostic procedure (X-ray, 
endoscopies or functional examination for diagnostic reasons). Only 3/14 patients 
were in the hospital without requiring any hospital-related diagnostic or 
therapeutic procedure.   
Analgesic drug treatment was not adjusted during hospitalization in 28/67 (42%) 
patients. Twenty-four of these 28 patients (86%) needed hospital specific 
treatments while 4/28 didn’t. The hospital specific treatments were: additional 
nursing care (n=4), radio- (n=9) and chemotherapy (n=6), disphosphonates (n=1), 
parenteral feeding (n=1), placement of a Cantor drain (n=1), rehydratation (n=2) 
and placement of a cystofix (n=1). Ten non-hospital specific treatments were 
done in 2/28 patients without a hospital specific treatment and in 8/24 patients 
from the hospital specific group: hormonal treatment (n=4), antibiotics (n=3), 
anti-coagulation (n=1) and corticosteroids (n=2). In the 4/28 patients who didn’t 
use any hospital specific treatment, 1 patient didn’t use neither any diagnostic nor 
a therapeutic or care facility of the hospital and this patient left the hospital 1day 
after admission. Two patients underwent only diagnostic procedures and they 
were advised against further antitumoral treatment, in one  patient a symptomatic 
treatment with corticosteroids was started. The fourth patient started hormonal 
treatment after diagnostic work-up. 
 
There were 57 hospital specific treatments (32/39 and 25/28) and 31 non-hospital 
specific treatments (21/39 and 10 /28) performed in the 67 patients that were 
admitted by emergency for pain. There were only 3/39 and 1/28 patients admitted 
by emergency who didn’t require any diagnostic nor therapeutic hospital specific 
procedure. There is no statistical significant difference in the hospital specific 
treatments between the patients who needed and the patients who didn’t need 
adaptation of analgesics  (p = 0.36 Fischer’s Exact Test). 
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Table 4: Hospital specific treatments and non-hospital specific treatments  
given  during the hospitalization. 
 
Adaptation of 
analgesics (N = 39/67) 
No adaptation of 
analgesics (N = 28/67) 
 
Hosp. Spec. 
Treatment 
(N= 25/39) 
Non. Hosp 
Spec. Tr. 
(N=14/39+ 
5/25) 
 
Hosp. Spec.
Treatment 
(N = 24/28) 
Non Hosp. 
Spec. Tr. 
(N= 2/28 + 
8/24) 
 
Hosp. 
Specific.  
Treatment 
Additional care 9  4  13 
Radiotherapy 8  9  17 
Chemotherapy 7  6  13 
Diphosphonates 1  1  2 
Referral to surgeon 1    1 
Blood transfusion 1    1 
Parenteral feeding 1  1  2 
Ascites puncture 2    2 
Cantor drain    1  1 
Port-à-Cath  1    1 
Thoracic Drain 1    1 
Rehydratation   2  2 
Hormonal treatm.    4  
Rectal clysma  1    
Urinary catheter  2 (Cystofix) 1  1 
Antibiotics  3  3  
Anti-coagulation    1  
Corticosteroids  3  2  
Change analgesic 
therapy 
 9    
Ant-emetics  1    
Oxygen  1    
Wound care  1    
Total 32 21 25 10 57 
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2.3.6 Duration of hospitalization 
 
Table 5 shows the median hospitalization duration in function of the treatment 
that was given. Chemotherapy patients remained in hospital for a median 
duration of 16.6 days, while the 17 patients who were irradiated had a median 
hospitalization of 15 days. Whether medical pain treatment was adjusted (n = 
39/67) or not (n = 28/67), the median duration of hospitalization in both 
situations was nearly 11 days (respectively 10.7 and 10.5 days). Hospital 
intervention restricted to nursing care and adjustment of analgesic drugs, without 
chemo- or radiotherapy, resulted in a median hospitalization of 9.1 days.  When 
only the analgesic treatment was adapted without need for nursing care, without 
chemo– or radiotherapy, then the median hospitalization time was 7 days. The 
shortest stay was noted for patients to whom only additional care was offered, 
without chemo- or radiotherapy and without change in analgesic drug therapy. 
For these patients, a median hospital stay of only 5.5 days was registered. There 
is a significantly longer hospitalization for patients treated with chemo- or 
radiotherapy compared with all the others (p= 0.0003 t-test) 
 
Table 5: Mean duration (days) of hospitalization in function of therapy. 
 
Hospital treatment Hospitalization duration (d) Patients(N) 
Chemotherapy 
Radiotherapy 
Adaptation of analgesics 
No adaptation of analgesics 
Care + pain treatment  
Analgesic treatment  
Other * 
Only additional care  
16.6  (range 4-34) 
15    (range 1-37) 
10.7  (range 1-34) 
10.5 (range 1-37) 
9.1  (range 1-20) 
7    (range 1-34) 
6.4 (range 1-15) 
5.5 (range 3-8) 
13 
17 
39 
28 
8 
15 
12 
2 
 
*Corticoids (n=2), anticoagulants, cystofix, disphosphonates, rehydratation, 
Cantor drain, parenteral nutrition. 
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2.3.7 Patient outcome  
 
Within 8 days could 24/67 patients return home while 9/67 others died in the 
hospital (together 49%), 12 patients left the hospital after 9-14days and 3 patients 
died in the hospital during this second week (together 22%). Eight patients 
remained 15-21 days while 4 others died in this third week (together 18%).  
Finally, 5 patients were hospitalized for 21-42 days while 2 other patients died 
during this hospitalization (together 10%) (Figure 2). All the discharged patients 
(49/67=73.1%) returned home except one patient who moved to a palliative care 
unit (n = 1); 18/67(=26.9%) patients died in the hospital after a mean stay of 11 
days. 
 
Figure 2: Number of patients that died or were discharged per week after   
hospital admission in emergency. 
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2.4 Discussion 
 
The emergency ward of the hospital functions as a crisis center for all the 
problems of the home cared palliative cancer patients that can’t be solved at 
home.  It is striking to see that these patients rarely enter during the weekend 
when the available professional care at home is reduced (Figure 1).  The patients 
mainly came in from Monday to Friday, with a higher frequency on Monday and 
Tuesday.  The increased admittance in emergency at the beginning of the week 
could suggest that the patients would like to first get some advice from their 
general practitioner before they definitely decide to come to the hospital.  This is 
also reflected by the 25/25 referral letters when the general practitioner sent the 
patient in emergency to the hospital, but also by the high number (19/42) of 
referral letters when somebody else was the driving force leading to 
hospitalization. The total of referral letters is 44/67 (=66%). This proves the 
important function of the general practitioner as “ health care manager” for 
palliative cancer patients.  
 
It is possible that during the weekend the family members are more involved in 
caring for or visiting the patient than on week days and that they become 
convinced that further home care is inadequate, or too difficult for the patient and 
the family, or even becomes impossible. This family perception and initiative can 
add to the relative excess of emergencies on Monday and Tuesday. 
 
All cancer types are responsible for emergency admissions in the same relative 
proportion as they occur in our oncology department (Table 1). No specific tumor 
type seems more eligible than others for emergency hospital admission.  
 
Poorly controlled pain was the main reason for admission in 67/124 (59%) 
emergencies in advanced cancer patients during the 3 month study period (Table 
2). This high frequency is confirmed in the literature. Pain (46-71%) and general 
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weakness or fatigue (43-82%) are the most frequent symptoms in advanced 
cancer patients. A survey of 1102 consecutive admissions to a specialty hospital 
devoted to the care of patients with advanced cancer revealed that on presentation 
73% had pain and 38% of them even had severe pain (9). In our study, pain was 
the sole symptom responsible for 17/67 (25%) emergencies. This fits well with 
the published data. The family and the general practitioner find that the main 
reason to refer a patient to a palliative care program is pain (29%), followed by 
terminal care (17%), home support (17%), psychosocial support for the patient 
alone (10%), psychosocial support for both patient and family (10%) or for the 
family alone (10%) and management of other symptoms (7%) (12). In this study, 
50/67 (75%) patients had 1 to 3 symptoms other than pain at hospital entry. This 
proves that in the majority of advanced cancer patients pain is not the sole 
symptom that has to be treated, although it is the most frequent one and the 
symptom that has the most impact on the care of palliative patients.  Pain 
assessment and pain relief measures should be a priority for all cancer caregivers 
during both active cancer treatments and the palliative care period.  Palliative 
care cannot be limited to just pain treatment; adequate control of the other 
symptoms is essential as well.  
 
Better communication between physicians concerning pain treatment in the 
different palliative care settings will probably shorten the time that is necessary to 
relief cancer pain for individual patients. 
 
Eighty-eight percent of the patients were referred to or entered the hospital for 
therapy (Table 3) and 92% of the patients  received some treatment (Table 4), of 
whom 73% (25/39 + 24/28) actually received hospital specific therapy. It seems 
astonishing that in 36/67 (53.7%) of these far advanced and no longer treated 
palliative patients an anti-tumor treatment was re-established: 17 radiotherapy, 13 
chemotherapy, 4 hormonal therapy and 2 disphosphonates. In the Memorial-
Sloan-Kettering Cancer Center an etiological treatment was started in two thirds 
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of the patients with “refractory pain” after a diagnostic procedure (28). This 
proves that medical decision making in cancer patients also in the palliative care 
phase is a dynamic process.  New pain patterns ask for new deliberations 
concerning etiological or symptomatic treatment. Many pain symptoms and 
syndromes in cancer patients can be alleviated by anti-tumor therapy. A total of 
57 hospital-specific treatments were performed in the 67 patients and in addition 
31 non-hospital specific treatments were initiated (Table 4). This holistic 
approach is only possible when enough experts from different disciplines are 
consulted soon after the patient enters the hospital. It is the aim to discharge the 
palliative patient as soon as possible for further home care after effective 
treatment. In this study 35.8 % of the patients were back home in less than 8 days 
and 53.7% were home within 14 days while respectively 13.4 and 4.4% of the 
patients died in the first and second week of hospitalisation (Figure 2). This 
implies that 71.6% of the emergency patients are already discharged out of the 
hospital at day 15. The more treatment that is required, the longer the patients are 
hospitalized. Patients treated with chemo- and radiotherapy stayed statistically 
significantly longer in hospital (15-17d.) than others (<10d.) (Table 5). This 
suggests that the hospital caregivers were aware of and considered the wish of the 
palliative cancer patients to return to the home care system as soon as possible. 
The weakness or fatigue, the pain or the deteriorated general condition in most 
patients may not allow to perform the more labor intensive diagnostic work-up 
(68% needed these) and treatments (73%) on an ambulatory basis.  
 
Only 4/67 (6%) of the patients was hospitalized without need of the diagnostic or 
therapeutic infrastructure of the hospital. This indicates that the home caregivers 
and the patients have realistic expectations on what the hospital infrastructure and 
expertise can provide. Sometimes it is suggested that the home caregivers transfer 
their terminally ill patients to the hospital just before dying, maybe as a result of 
insufficient control of physical symptoms and psychological pressure. There is no 
basis for this statement in this analysis since only 3/67 patients (4.5%) died 
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within 24 hours, another 4 patients (6%) died during the first week of 
hospitalization and the other terminally ill patients (11/67 or 16%) died between 
8 and 37 days after emergency admission. 
Many caregivers are convinced that palliative care is the exclusive responsibility 
of the home care and that hospitals have to implement all available scientific 
knowledge to cure diseases and to maintain patients’ health as long as possible.  
However the home care needs support from and close cooperation with the acute 
hospital as a back-up system. Sometimes the hospital has to take over the care, 
for a short time or sometimes permanently, when home caregivers and the family 
or friends are no longer able to provide adequate support due to the intensity or 
complexity of the symptoms or for social reasons. This study provides evidence 
for the complementary role and effectiveness of rapid relief of symptoms in an 
acute oncological ward, when home care can no longer cope with refractory pain 
or other symptoms in advanced palliative cancer patients. 
 
Acute oncological hospital wards have a twofold task for advanced palliative 
cancer patients who enter in emergency. They have to provide well organized 
diagnostic and therapeutic procedures of limited duration to relieve symptoms, as 
far as possible, by a range of specific hospital based treatments, allowing the 
home care team to take over the further palliative care as soon as possible. For 
those patients who will die during the hospitalization (18% in our analysis), they 
have to provide effective pain and symptom control in an environment where 
social, psychological and spiritual issues are considered, to guarantee a peaceful 
death with dignity, the patient being surrounded by his relatives and competent 
professional support where necessary. 
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2.5 Conclusion 
 
Cancer pain is frequent (>50%) in palliative patients and is the only symptom 
responsible for an emergency hospital admission in many patients (25%). But 
there is more than pain, many patients have 1 to 3 additional symptoms or 
complaints , that also need to be relieved as quickly and as well as possible. This 
big challenge is not feasible for one single discipline. Nurses, physicians of 
different specialties, psychologists, clergy and social workers have to cooperate 
to relieve the patient and his family as much as possible. This study shows the 
wide variety of therapeutic options that had to be offered to 67 far-advanced 
palliative cancer patients admitted to the hospital in emergency for pain and other 
symptoms. An etiological treatment has to be started where possible.  
 
The acute wards in the cancer hospital have an important task to provide rapid 
diagnostic and therapeutic strategies for the many far-advanced palliative 
cancer patients. Fifty-three percent of the patients did return home within 2 
weeks after emergency hospital admission for pain and other symptoms. 
Although they are already palliative patients, many of them will still profit 
from newly started anti-tumour treatments with chemo-, radio- or hormonal 
therapy. Assessment and adaptation of symptomatic pain treatment has 
frequently to be done as well. 
 
Pain and symptom control are very frequent palliative issues with a heavy 
emotional, social and financial burden for the patient and the community 
(management, staff, investment and costs). The knowledge of the palliative 
principles, the attitude to manage these,  must form the basis for good clinical 
practice by all caregivers, both in the hospital and in the home care. Quick and 
effective management of these problems is a challenge for all concerned. People 
who are responsible for medical education and management have to consider 
these issues. 
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This chapter has been published in  
Current Medical Research and Opinion 2002; 18: 488-498. 
 
3.1 Patients and Methods 
 
3.1.1 Study design 
 
Adult patients with cancer pain caused by the presence of a histologically 
confirmed and incurable malignant disease and for who even palliative systemic 
anti-tumor therapy no longer was available, were eligible for this open-ended 
Belgian multicenter evaluation of TTS-fentanyl. Patients were to take opioid 
analgesia according to step III of the WHO analgesic ladder (77) and to have an 
estimated survival of at least 3 months. Excluded from the study were patients with 
a history of allergy to opioids, a history of narcotic abuse prior to their diagnosis of 
cancer, active skin disease precluding application of the transdermal system, or a 
clinically relevant history of pulmonary failure (CO2 retention), renal dysfunction 
(serum creatinine > 2.0 mg/dl) or liver dysfunction (serum bilirubin > 2.0 mg/dl). 
The study was conducted in accordance with the Declaration of Helsinki. Full 
approval of the protocol was obtained from the local independent ethical 
committees. All patients provided informed consent before study entry. 
Enrolled subjects were first stabilized on oral morphine to obtain adequate pain 
relief, except for patients already taking TTS-fentanyl or oral morphine and patients 
unable to continue taking oral morphine (e.g. swallowing problems, unacceptable 
morphine-related constipation). These patients entered the study without prior 
stabilization. Patients using opioids other than oral morphine and TTS-fentanyl 
prior to study entry were converted to oral morphine according to the standard 
“opioid analgesic conversion table” (78) and titrated to a stable dose.  
After stabilization on oral morphine, patients were switched to an equi-analgesic 
TTS-fentanyl dose, according to the “P.O. morphine sulphate to TTS-fentanyl 
Conversion Scheme” with a conversion ratio 150:1 (79). In addition to the study 
drug, patients used immediate release morphine on an as-needed basis as rescue 
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medication for incident or breakthrough pain. Oral morphine in a dose of 1/12 to 
1/6 of the daily equivalent TTS-fentanyl maintenance dose in a concentration of 1 
or 5 mg/ml. solution could be taken every 4hr. if pain occurred.    
 
Dose adjustments were permitted at each patch renewal (every 3 days). The TTS-
fentanyl dosage titration was performed with stepwise increments (or decrements) 
of 25 µg/hr., based on patients’ daily supplemental analgesic requirements, 
balancing adequate pain control with an acceptable level of side effects and a 
minimal need for supplemental rescue medication.  
 
Concomitant use of fixed doses of non-steroidal anti-inflammatory drugs 
(NSAID’s), paracetamol or aspirin was allowed as far as the initial dose at study 
entry remained unchanged. Treatment initiation or dose adaptations were only 
permitted if judged absolutely necessary by the investigator. This also applied to 
potential central nervous system depressants such as anxiolytics, hypnotics and 
tricyclic antidepressants. The use of anti-emetics, antihistamines and laxatives was 
not restricted. 
 
3.1.2 Assessments 
 
Patients were evaluated periodically at least every 28 days. It was the aim in this 
study to keep the pain equal or below 3.5 on a VAS-pain scale from 0 to 10 for all 
patients. TTS-fentanyl dose adjustments and rescue morphine requirements were 
recorded at each follow-up. Drug tolerability was assessed by documenting all 
adverse events and side effects. The occurrence of constipation was reported using a 
3-point scale (mild-moderate-severe) with particular attention to the use of 
laxatives. Reasons for study discontinuation were reported. In addition, the 
convenience of the patches was evaluated using a 4-point scale (unsatisfactory, 
moderate, good, and excellent).  
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3.1.3 Analysis 
 
Descriptive statistics were performed regarding baseline characteristics and periodic 
assessments. The last documented visit was defined as the individual study 
endpoint. The type and incidence of all adverse events recorded during the study 
were registered, with special attention to reasons for study discontinuation.  
The Safety population consisted of patients that received at least one dose of TTS-
fentanyl. The Evaluable population was defined for analytical purposes and 
consisted of subjects who took at least 1 dose of study medication and had 
information available from at least 1 on-treatment visit, in addition to the baseline 
data. In both populations, two subpopulations were compared to the whole 
population: the elderly patients, consisting of all subjects of 60 years and older, and 
the opioid naïve patients, consisting of patients who started directly on TTS-
fentanyl without prior step-up pain management with weak or strong opioid 
analgesics, skipping the second step of the WHO analgesic ladder. For sample sizes 
smaller than 20 patients, no analyses were performed.  
The drug doses were non-Gaussian distributed. Most patients used relatively low 
doses of opioids while there were few patients treated with huge doses of opioids. 
Therefore the medians are reported, the mean doses are given for the completeness 
of the information, where this is appropriate. When data were parametric (age 
distribution), the means are given. 
 
3.1.4 Medication 
 
TTS-fentanyl (Durogesic® patch, Janssen Pharmaceutica), a transdermal opioid 
delivery system, releases fentanyl from a reservoir through a rate-limiting 
membrane to the skin and a depot of the drug concentrates in the subcutaneous 
tissues. After approximately 12 hours steady-state plasma fentanyl concentrations 
are reached and are maintained for about 72 hours. Fentanyl patches are available in 
25, 50, 75, and 100 µg/hr. dosages. Multiple patches are applied at the same time if 
doses above 100 µg/hr. are needed. 
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3.2 Results 
 
3.2.1 Subject enrollment and reasons for discontinuation 
 
Between June 1994 and September 1997, a total of 663 patients with a wide range 
of malignancies were recruited by 54 Belgian investigators and enrolled in this 
multicenter study (Table 6). Of these, 661 patients took at least 1 dose of study 
medication (Safety population).  
 
Table 6: Number of patients in each population. 
Safety Population Evaluable Population 
>1dose of trial medication 
Baseline data 
 
> 1 dose of trial medication 
>1 on-treatment visit data 
Total n = 661 n = 455 
Elderly n = 341 n = 235 
Opioid naïve n = 55 n = 30 
 
Despite an estimated survival at inclusion of at least 3 months, more than 
one third of patients (37%, n=246) dropped out of the study during the first 
month of therapy. The number of patients further declined steeply, leaving 
24% (n=162) of patients included after 3 months and 10% (n=65) after 6 
months. The major reason for premature discontinuation of the study was the 
occurrence of death (61% of patients, n=397), mainly related to cancer 
progression. Adverse experience was indicated as one of the reasons for 
study discontinuation in 286 patients, mostly reported in combination with 
the previously mentioned cancer death (n=241), together with other reasons 
for withdrawal (n=27) or as unique reason (n=18).   
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Other reasons for withdrawal from the study were insufficient response 
(n=111), loss to follow-up (n=50), uncooperativeness (n=21) and consent 
withdrawal (n=3).  
 
3.2.2 Demographics and baseline characteristics  
 
Both genders were equally distributed over the study population (male/female ratio 
= 1.1). Patients’ mean age (± standard deviation) (SD) was 59 (± 13) years, ranging 
from 18 to 91 years. More than half of the patients (n=341 or 52%) were 60 years or 
over. The mean (± SD) age of these elderly patients was 69 (± 7) years.  
 
A total of 455 patients had data available at baseline and at least 1 on-treatment visit 
(Table 6). In these patients (=Evaluable population), tumor history, previous and 
concomitant therapy, treatment duration and applied doses were assessed. 
 
3.2.3 Tumor history (Evaluable population) 
 
Primary tumors were most frequently localized in the gastrointestinal tract (n=97; 
21%), followed by breast (n=79; 17%), lung (n=51; 11%) and prostate (n=41; 9%). 
The median interval between diagnosis of the primary tumor and study inclusion 
was 18 months.  
 
3.2.4 Previous therapy and concomitant therapy (Evaluable population) 
 
In the period of 2 weeks prior to study entry, analgesic therapy mainly consisted of 
strong opioids, often associated with non-opioid analgesics. Morphine intake was 
present in the majority of patients (89%) but also totally opioid naïve patients were 
included. Of 55 opioid naïve patients who entered the study, 30 patients were 
evaluable at baseline and had at least 1 on-treatment visit (6.6% opioid naïve 
patients in the Evaluable population).  Paracetamol was the most frequently used 
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non-opioid analgesic, taken as a single preparation (11%) or combined with codeine 
(11%); approximately 15% of patients used NSAID’s. 
During the study, patients often used paracetamol, alone (41%) or combined with 
codeine (11%) to supplement pain control; NSAID’s were taken by 31% of patients. 
Antidepressant intake was found in 7% and anticonvulsants in 5% of patients. 
 
3.2.5 TTS-fentanyl treatment and rescue morphine use (Evaluable 
population) 
 
3.2.5.1 Conversion from oral morphine to TTS-fentanyl at baseline 
 
Information on the precise daily morphine equivalent dose at study entry was 
available for 75% of patients; the median (95% CI) dose was 120 mg/day (90-120 
mg/day). More than 85% of these patients took daily oral morphine doses higher 
than 40 mg. Patients were converted to equi-analgesic TTS-fentanyl doses while 
continuing the use of rescue morphine for breakthrough pain. Most patients (61%) 
started therapy at the lowest dosage of the patches (25 µg/hr.) but 29% of patients 
were directly converted to higher TTS-fentanyl doses of 50 or 75 µg/hr. In 10% of 
patients therapy was initiated at 100 µg/hr. or higher (Figure 3). The median 
baseline TTS-fentanyl dose (95% CI) was 25 (25-25) µg/hr.; the mean was 46.6 
µg/hr., ranging from 25 to 800 µg/hr. 
 
3.2.5.2 Elderly patients 
 
Morphine doses at study entry were only slightly lower in the group of elderly 
patients (median morphine dose (95% CI) of 100 mg/day (70-120)) compared to the 
whole Evaluable population with a median morphine dose of 120 mg/day (90-120). 
We found in the elderly that the older the patient, the lower the morphine dose that 
was applied.  The baseline morphine use in the 60-69 age group (median dose of 
120 (80-140) mg/day; n=99) was still comparable to the total Evaluable population, 
it was clearly lower in the group of patients aged 70-79 years  (median daily dose of 
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90 mg/day (60-120); n=62) and in the group of patients of 80 years and older 
(median dose of 60 mg/day (30-120); n=16). However the number of patients in the 
subcategory of 80 years and older was already relatively small at baseline. 
Figure 3: Percentage of patients (total group and ≥60 years) in the Evaluable 
population, receiving the various initial median doses of TTS-fentanyl (µg/hr). 
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The median TTS-fentanyl baseline dose (95% CI) used in the elderly patients was 
25 µg/hr. (25-25), comparable to the total patient group, but less frequently 
extremely high individual start doses were found (min-max: 25-225 µg/hr). A total 
of 27% of elderly patients initiated TTS-fentanyl therapy at dosages of 50 to 75 
µg/hr, and 8% at 100 µg/hr. or higher (Figure 3). While the median doses of the 
elderly were comparable to the total group, the mean TTS-fentanyl dose at baseline 
was 46.5 µg/hr. in the 60-69 years age group, 38.6 µg/hr. in the 70-79 years age 
group and only 29.5 µg/h. in the group of patients of 80 years and older. This 
reflects that older patients used lower mean TTS-fentanyl start doses which is in 
accordance with the lower morphine doses used at study entry in this age group.  
µg/h. TTS-fentanyl 
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3.2.5.3 Duration of the treatment phase 
The duration of treatment of patients who entered the study showed large inter-
individual variations ranging from a few days to 2½ years. In the Evaluable 
population (n = 455), the median (95% CI) duration of the TTS-fentanyl treatment 
phase was 81 days (range 70-90).  
The data regarding the duration in the elderly patients (n = 235 and median duration 
of 76 days (range 62-90)) showed that tolerability of TTS-fentanyl in long-term 
therapy in the elderly patients was similar to the whole Evaluable population. In 
contrast, the median duration of the treatment phase was longer in the opioid naïve 
patients (107 days, with a range of 56 to154).  
 
3.2.5.4 TTS-fentanyl dosage and use of rescue morphine over time. 
TTS-fentanyl dose adjustments, relative to the previous treatment period, were 
recorded at each 4-weekly visit. The use of morphine solution, intended to treat 
breakthrough or incidental pain during the different study intervals, was 
documented in addition. 
The median (95% CI) dose of rescue morphine used was 20 (10-30) mg/day at 
month 1 and 10 [0-20] mg/day at endpoint.   If the rescue morphine doses were 60 
mg/d. or higher in the individual patients, then the next TTS-fentanyl application 
was incremented with 25µg/hr. 
 
TTS-fentanyl dose adjustments are given in Figure 4. It shows that dose increases 
of TTS-fentanyl were most frequent at the beginning of the study (67% of patients 
at month 1 visit) when the dropout rate related to disease progression also was 
highest. During the month prior to individual study endpoints, 54% of patients 
needed TTS-fentanyl dose increments. A rather similar course was found for the use 
of rescue morphine with 61% of patients using morphine doses during the first 
month of treatment, and 55% during the month prior to individual study endpoints.  
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Figure 4: Percentage of patients (n = 455 at baseline) who needed TTS-fentanyl 
dose increments, TTS-fentanyl dose decrements or who used rescue morphine 
during the previous treatment month in the Evaluable population. The right point  
(endpoint) corresponds to the last documented treatment month for all patients,  
independent from the duration of the therapy. The values in italic represent the total  
number of patients evaluated at each time point.  
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Dose decreases for TTS-fentanyl were relatively rare and were only seen in 6% of 
patients after 1 month of treatment and in 10% at the individual study endpoints. 
The median (95% CI) TTS-fentanyl dosage at endpoint was 100 (100-100) µg/hr. in 
this population, ranging from 25 to 950 µg/hr. The interpretation is biased by the 
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non-Gaussian distribution of TTS-fentanyl dosing in cancer pain management and 
confounded by the high initial patient dropout rate.  
Therefore mean dosages for the total group and for the various elderly age groups 
are given in Figure 5 to illustrate that dose increases were most common during the 
first treatment month, slowly increased until month 4 but stabilized by month 5. In 
the different primary tumor groups, a similar time course of TTS-fentanyl dosage 
was found. Figure 6 represents these data per primary tumor class, insofar as more 
than 20 patients were available.  
 
Figure 5: Mean TTS-fentanyl dose (± SD) in µg/h. in the Evaluable population in 
function of age and time. The right point (endpoint) corresponds to the last 
documented treatment month for all patients, independent of the duration of 
therapy. The values in italic represent the total number of patients evaluated at 
each time point. 
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Figure 6: Mean TTS-fentanyl dose (± SD) during long-term therapy per primary 
tumour class in the Evaluable population. The right point (endpoint) corresponds to 
the last documented treatment month for all patients, independent of the duration of 
therapy.  
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3.2.5.5 Elderly patients 
 
The time patterns of TTS-dose adjustments and use of morphine for breakthrough 
pain in the elderly patients were comparable to the total evaluable patients (data not 
shown). TTS-fentanyl dose increases were found in 68% and 54% at month 1 and at 
patient individual study endpoint respectively. Dose decreases were found in only 
4% and 9% respectively.  
 
Elderly patients from the subcategory of 60 to 69 years (n=130 at baseline) showed 
mean TTS-fentanyl dosages over time comparable to the total Evaluable population. 
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In the 70-79 age group (n=83 at baseline) and in the group aged 80 years and over 
(n=22 at baseline), lower mean TTS-fentanyl dosages were found respectively at 
month 3 and 1(Figure 5). The number of patients in these age subcategories was 
already limited and was still rapidly decreasing during the first months of the study; 
data are only shown for sample sizes of 20 patients and more. Taking into 
consideration the wide range of doses of TTS-fentanyl applied (25-500 µg/hr), the 
dose reduction that occurred in the 70-79 year age group at month 3 (Figure 5), 
should be interpreted with caution as only 20 patients were involved at this time 
point. The death of 1 or 2 high dose fentanyl consumers can cause such an effect. 
Looking further at month 4 (n=16; not shown), the mean TTS-fentanyl doses 
reached again 96.9 µg/hr, while the mean dose for the total group is 132, 5 + 
11µg/h. at month 4.   Similarly, the number of patients in the subcategory aged 80 
years and over was very limited (respectively 20 patients and 6 patients at months 1 
and 3). In the elderly patients, the median (95% CI) TTS-fentanyl dosage at 
endpoint was 100 (75-100) µg/hr. as it was for the total group 100 (100-100) µg/h. 
The number of elderly subjects and the total group patients using rescue morphine 
for breakthrough pain was 61% and 55% respectively at month 1 compared to 59% 
and 54% respectively at endpoint.  
 
3.2.5.6 Opioid naïve patients 
 
TTS-fentanyl doses in the opioid naïve patients were comparable to the total 
Evaluable population, starting with the lowest dosage available (median (95% CI): 
25 (25-50) µg/hr) to a median (95% CI) delivery rate at study endpoint of 100 (75-
150) µg/hr. Less rescue morphine was used. The median (95% CI) rescue morphine 
dose was 10 (0-40) mg/day after one treatment month and 5 (0-50) mg/day at 
endpoint. 
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3.2.6 Tolerability data (Safety population) 
 
3.2.6.1 Overall tolerability  
 
Serious adverse events (death or hospitalization) 
In this terminally ill patient population, the reported serious adverse events in 
61.6% of the subjects (n=407) mainly included death, which never was related to 
the study drug in the opinion of the investigators and always related to the 
progression of the underlying disease.  Eighteen serious adverse events other than 
death occurred in 15 patients, namely moderate to severe injury (n=13, falling, 
hemorrhage, haematoma, fractures, incised or abraded wound), moderate 
constipation (n=1), severe respiratory depression (n=1) and abnormal laboratory 
values (twice in the same patient). One case of overdosing occurred (n=1). The 
outcome of these adverse events was complete recovery, except for 8 cases of 
injury that were still present at study endpoint and one patient died of the injury.  
 
In only in 2 of these 15 patients, the investigators indicated that the adverse events 
could possibly be related to the study drug. The first case concerned a 56-year-old 
male patient suffering from carcinoma of the tongue base who was converted from 
oral morphine 120 mg. daily to TTS-fentanyl 50 µg/hr. Nine days after conversion 
the patient developed severe respiratory depression with favorable outcome. He 
discontinued TTS-fentanyl therapy. The second case was a 42-year-old female 
patient with lung carcinoma who developed drug-related moderate constipation 
together with injury for which she was hospitalized. Recovery was reported and the 
study drug was continued. No other serious adverse events, deaths inclusive, were 
found related to the study drug.  
 
The elderly patient group demonstrated a slightly but statistically not significant 
higher incidence of serious adverse events, 64.8% compared to 61.6% for the total 
patient group. This difference was completely explained by the increased number of 
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non-drug-related deaths in the advanced age group. Other serious adverse events in 
this specific patient group were injury (n=6) and the case of overdosing. In the age 
group of patients 70 years and older, no serious adverse event was reported, with 
the exception of death, probably related to the underlying disease.  
 
Non-serious adverse events (hospitalisation not necessary) 
Non-serious adverse events consisted mainly of gastro-intestinal, psychiatric and 
nervous system disorders: 5.1% of the patients developed nausea, 4.4% 
vomiting, 2% confusion, 1.8% somnolence and 1.1% headache. Frequency and 
severity of constipation were evaluated separately and in-depth at each monthly 
visit and the results are detailed in the next paragraph. In contrast to these results, 
constipation was rarely (0.8%) reported as an adverse event as such. Moderate 
dyspnoea was found in 0.8% of patients. Four patients experienced patch related 
adverse events (0.6%). In the elderly patients, the same type and relative 
frequency of adverse events was found but the overall incidence was slightly, but 
not statistically significantly, higher (Table 7). In these 661 patients, 13 patients 
(1, 9%) were confused on occasion and all of them were ≥60 years. Somnolence 
was present in 1, 8% (12/661) but 9 of these 12 cases were registered in the older 
patients (≥60y) (9/341=2, 6%) and only 3 in the younger group (<60y) (3/310= 
0, 9%).  
 
Discontinuation due to adverse events 
An adverse event, other than death, was the reason for discontinuation of the 
study in only 27 patients (4.1%). According to the investigators 2/3 (67%) of 
these cases were possibly drug-related; most frequent were nausea (n=7), 
vomiting (n=4) and confusion (n=3). Especially a steep increase in opioid dose 
promotes confusion in elderly patients. Decreasing the opioid dose, change of 
administration route or, a rotation of opioids can solve this side effect. 
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Opioid naïve patients 
In the opioid naïve patients in the study (n=55) no serious adverse event was 
registered, except for non-drug-related death in 34 patients (61.8%). Two patients 
discontinued the study due to an adverse event (1 subject because of vomiting and 1 
subject because of headache, nausea and vomiting). The total adverse event rate 
was comparable to the total Safety population. None of the patients experienced 
respiratory depression (Table 7). 
 
Table 7: Number of patients (%) reporting adverse events (Safety population). 
 Total 
n=661 
Elderly  
n=341 
Opioid naïve 
n=55 
Any adverse event  460 (69.6) 255 (74.8) 38 (69.1) 
General disorders  
    e.g. death, injury 
423 (64.0) 232 (68.0) 35 (63.6) 
Nervous system disorders 
   e.g. headache, dizziness 
23 (3.5) 16 (4.7) 2 (3.6) 
Gastro-intestinal disorders  
   e.g. nausea, vomiting 
54 (8.2) 37 (10.9) 4 (7.3) 
Psychiatric disorders  
   e.g. confusion, somnolence 
34 (5.1) 24 (7.0) 2 (3.6) 
Respiratory system disorders 
   e.g. dyspnoea, coughing 
9 (1.4) 6 (1.8) 1 (1.8) 
Skin & appendages disorders  
   e.g. increased sweating, pruritus 
10 (1.5) 8 (2.3) 1 (1.8) 
Urinary system disorders  
  e.g. haematuria, urinary retention
7 (1.1) 6 (1.8) 0 (0) 
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3.2.6.2 Constipation (Evaluable population) 
 
Frequency and severity of constipation were assessed separately and in-depth at 
each monthly visit. In contrast, in the Safety population constipation was rarely 
(0.8%) reported as an adverse event as such. Therefore, constipation is discussed in 
relation to the Evaluable population, in which approximately 40% of patients with 
available data, reported mild to severe constipation at the monthly visits. This 
frequency remained relatively constant over the study period. The severity of 
constipation was also similar at the month 1 visit compared to study endpoint and 
not influenced by age (Table 8).  
 
Table 8: Number of patients (%) according to severity of constipation (Evaluable 
population) 
 
 Total Elderly 
 Month 1 Endpoint Month 1 Endpoint 
No constipation 229 (59) 237 (58) 120 (58) 117 (54) 
Mild constipation 75 (19) 80 (20) 40 (19) 46 (21) 
Moderate 
constipation 
62 (16) 69 (17) 35 (17) 41  (19) 
Severe constipation 22 (  6) 23 (  6) 11 (  5) 12 (  6) 
 
Only 6% of patients suffered from severe constipation at month 1 and at endpoint. 
In the other constipated patients, this was mild to moderate. There were no 
differences regarding the occurrence and mild or moderate constipation (incidence 
is for all between 16 and 21%) between the total population of evaluable patients 
and the elderly patients.  
Since patients included in this study associated both TTS-fentanyl therapy and oral 
morphine rescue medication, the occurrence of constipation could not directly be 
related to one of the drugs. More information about possible causal relationships 
could therefore be obtained by regrouping the patients to the respective applied 
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posologies. TTS-Fentanyl doses of 25-50 µg/hr were considered as “low dosages”; 
all doses of 75 µg/hr. and above were called “high doses”. The rescue morphine 
doses were classified in “low” (0-40 mg daily) and “high” doses (above 40mg 
daily). Table 9 shows the percentages of patients that reported constipation at month 
1 and at study endpoint for these subgroups.  
 
The total group: 
At month 1, the frequency of constipated patients with low dose morphine was 
respectively 36% (low dose fentanyl) and 37% (high dose fentanyl) and these 
figures did increase, but not statistically significantly (p= 0.062 Fisher’s Exact 
Test),   by increasing the morphine dose (50% and 47%). If at month 1 the fentanyl 
dose increased, the frequency of constipation remained stable at 37% for low 
morphine dose and at 47% for high dose  morphine (p= 0.58).  
 
At endpoint, the frequency of constipated patients with low dose morphine was 
respectively for low and high dose fentanyl 38 and 35%, but increased significantly 
(p= 0.0007) with increasing doses of morphine to 47% and 57% for low and high 
dose fentanyl. Increasing the fentanyl dose at endpoint did statistically (p=0.64) not 
increase the constipation frequency for low (38 tot 35%) or high (47 tot 57%) dose 
morphine using patients. 
 
The elderly group: 
At month 1, the frequency of constipated patients with low dose morphine was 42% 
under low dose fentanyl and 32% under high dose fentanyl and these figures did 
increase, not statistically significantly (p = 0.085), to 60 and 50%  by increasing the 
morphine dose. If at month 1 the fentanyl dose increased, the frequency of 
constipation even decreased from 42 to 32% for low dose morphine and from 60% 
to 50% for high dose morphine (statistically not significant p=0.458). 
At endpoint, the frequency of constipated patients with low dose morphine was 40 
and 38% for low and high dose fentanyl respectively. It increased statistically 
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significantly (p=0.0006) with increasing dose morphine to 63% and 67% 
respectively for low and high dose fentanyl. Increasing the fentanyl dose at 
endpoint did not statistically (p = 0.64) change the constipation frequency for low 
(40 tot 38%) or high dose morphine using patients (63 tot 67%). 
 
Table 9: Effect of opioid dose on constipation at month 1 and study endpoint 
(Evaluable population and the subgroup of elderly). Percentages of patients with 
constipation are presented according to the morphine dose (Low: 0-40 mg/day; 
High: > 40 mg/day) and TTS-fentanyl dose (Low: 25-50 µg/hr, High: ≥75 µg/hr). 
 
Evaluable 
population 
TTS-fentanyl   
Low dose 
TTS-fentanyl 
High dose 
Elderly  
patients 
TTS-fentanyl   
Low dose 
TTS-fentanyl 
High dose 
 M1 End M1 End  M1 End M1 End 
Morphine   
Low dose 
36 38 37 35 Morphine   
Low dose 
42 40 32 38 
Morphine 
High dose 
50 47 47 57 Morphine 
High dose 
60 63 50 67 
 
 
Elderly patients taking high doses of rescue morphine were even more prone to 
constipation (in 3 of the 4 subgroups over 60% of patients) than the whole 
Evaluable population. 
The prescription of concomitant laxatives was not restricted throughout the study 
period. After 1 month, 60% of the total Evaluable population and 65% of the group 
of elderly patients were taking laxatives. The use of laxatives further remained 
rather constant, in accordance with the frequency of constipation that also showed 
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little variation during the study period. Osmotic laxatives were the first choice for 
treatment, if necessary were natriumpicosulphate drops added, and further on an as 
needed basis a clysma could be given. 
 
3.2.7 Appreciation of the TTS-fentanyl patches (Evaluable population)  
 
Patients evaluated the ease of use of the patches on a 4-point scale: excellent –good 
– moderate – unsatisfactory (Figure 7). It appeared that more than 85% of the 
Evaluable population rated the convenience of the patches as “good to excellent”. 
After 1 treatment month and at study endpoint similar scores were found. Only 6% 
of patients were not satisfied. The opinion of the elderly subjects about the 
convenience of the patches was comparable. 
 
Figure 7: Percentage of patients in the Evaluable population and the elderly 
subgroup considering the ease of use of the patches excellent, good, moderate or 
unsatisfactory at month 1 and endpoint. 
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3.3 Discussion 
 
This large open-label study in real daily clinical practice confirms the good 
tolerability and convenience of long-term TTS-fentanyl use in cancer patients (80-
83). In contrast to classical clinical trials, this compassionate use program copes 
with an important inter-individual heterogeneity related to varying treatment 
durations, a wide range of TTS-fentanyl doses, differently progressing underlying 
diseases and different age populations.  
 
3.3.1 Study discontinuation 
 
At the moment this study was performed, TTS-fentanyl was new in Belgium and 
therefore its compassionate use probably often was reserved for terminally ill 
patients. A total of 61% of patients did not complete the planned 3-month study 
period because of death that in none of the cases was drug-related but mainly 
caused by progression of the underlying disease. This indicates that investigators’ 
prognosis at inclusion overestimated real survival time in a large number of 
patients.  
Insufficient pain relief led to treatment discontinuation of 17% of these cancer 
patients with poor life expectancy. They were further treated with systemic or 
epidural /intrathecal morphine administration. 
 
The third reason for study termination was the occurrence of an adverse event (not 
resulting in death), most frequently nausea, vomiting and confusion. Only 4.1% of 
patients withdrew from the study for adverse events, including 1.4 % non-drug-
related cases in the opinion of the investigator. 
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3.3.2 Tolerability 
 
Typical morphine-like side effects occur with TTS-fentanyl as with other strong 
opioids e.g. constipation, nausea, vomiting, somnolence and confusion. However, 
side effects and particularly constipation and sedation have been reported to occur 
less frequently with TTS-fentanyl compared to sustained-release oral morphine 
(84,85). In a compilation of TTS-fentanyl clinical trial data, nausea, vomiting, 
somnolence and confusion were previously reported to each occur in more than 
10% of patients (86). The current open-label study illustrates a less than 10% 
frequency of adverse events in this compassionate use program. This is probably 
attributable to a lower reporting rate, particularly in these terminally ill patients, in 
whom it not always is clear whether the disease or the treatment induced adverse 
events. One patient developed respiratory depression with favourable outcome but 
was withdrawn from the study. No other drug-related serious adverse events were 
reported, except for one patient who was hospitalized for injury and simultaneously 
suffered from drug-related moderate constipation. Skin tolerance to TTS-fentanyl 
was good; patch-related skin side effects occurred in only 0.6% of patients. Gastro-
intestinal disorders and psychiatric disorders were less frequent in this data series 
compared to other reports (80, 82, 87 and 88). Although it is generally accepted that 
patients with an increased risk for constipation should receive prophylaxis (89), the 
co-prescription of laxatives was relatively low in this open study (60% of patients 
and 65% of elderly patients were using laxatives). 
 
The fact that morphine was used as rescue medication in addition to TTS-fentanyl 
complicates the interpretation of side effects that might have been caused by either 
treatment regimens. This particularly applies to the interpretation of the constipation 
data. Interesting results were obtained comparing dose-relationships of morphine 
and TTS-fentanyl with respect to constipation. At least at a low dose of morphine, 
the rate of constipation was not found to be TTS-fentanyl dose related, even in the 
elderly (32 to 42%). In contrast, constipation was clearly more frequent (47 to 57%) 
in the patients using high doses of rescue morphine and particularly in elderly 
Longitudinal follow up of TTS-fentanyl patients    67 
patients (63 to 67% at endpoint). This is in line with data from clinical trials 
reporting that constipation occurred less frequently following TTS-fentanyl than 
with morphine administration (84). 
 
3.3.3 TTS-fentanyl treatment in different populations 
 
Whatever the population studied, a wide range of TTS-fentanyl dosages (max. 950 
µg/hr.) were used over different, sometimes long, periods of time (up to 2½ years).  
The appropriate initial TTS-fentanyl doses were derived from the existing opioid 
treatment during the stabilization phase. It has previously been estimated that the 
recommended dose-equivalent tables (conversion ratio 150:1) are very conservative 
(81, 89, and 90). The broad safety margin leads to a large proportion of opioid 
tolerant patients, namely those taking opioid doses equivalent to oral morphine up 
to 134 mg/day, all being converted to the lowest available TTS-fentanyl dose. This 
leads to frequent initial dose increments and might translate into initial TTS-
fentanyl under dosage, with patients dropping-out early due to insufficient response. 
Therefore, Breitbart et al. have recently proposed a more aggressive dose-
equivalence scheme (ratio 100:1) (90).  
 
TTS-fentanyl dose increments were most frequently found at the beginning of the 
study and stabilized by month 2. This probably reflects that patients with the fastest 
disease progression dropped out early. It also suggests that the recommended dose 
equivalence tables (150:1) are conservative, as mentioned in the preceding 
paragraph.  
 
Time courses of the frequency of rescue morphine use and TTS-fentanyl dose 
increases were superimposed showing that the guideline to replace all breakthrough 
morphine exceeding 60 mg/day by an equivalent dose of TTS-fentanyl 25µg/hr. 
was followed in an excellent way by the investigators. Dose decreases were rare, 
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which reflects that the risk of prescribing overdoses of TTS-fentanyl is relatively 
low in patients where anti-tumor treatment no longer is possible. 
 
The total group of elderly patients of 60 years and over could not be differentiated 
from the whole patient group, neither with respect to dosage scheme nor to 
tolerability, except for a slight increase of non-serious adverse events. However,  
‘within’ the group of elderly patients, consumption of TTS-fentanyl decreased with 
increasing age and was lowest in the category of patients of 80 years and over. 
Although sample sizes were limited in these age subcategories, this indicates 
perhaps that very old patients communicate pain less well or that investigators are 
more prudent in prescribing opioids. Overall, our results confirm previous findings 
of Jakobsson (91) who demonstrated that it is possible to obtain safe pain control 
with TTS-fentanyl in terminally ill patients, irrespective of age. 
 
A total of 55 completely opioid naïve patients entered the study and started TTS-
fentanyl therapy directly, omitting WHO step 2 of the analgesic ladder. Compared 
to their opioid non-naïve colleagues, these patients were characterized by longer 
treatment duration probably because they were in an earlier phase of their cancer 
stage with less painful lesions. With regard to the median TTS-fentanyl start and 
endpoint doses, the opioid naïve population could not be differentiated from the 
total population, but a lower need for rescue morphine was found. The tolerability 
was similar to that in the strong opioid tolerant patients, with none of these patients 
developing respiratory depression. It appears that starting directly with appropriate 
TTS-fentanyl was well tolerated in this group of opioid naïve patients. A similar 
experience in a small study of 28 patients has been reported by Vielvoye-Kerkmeer 
(92). 
Longitudinal follow up of TTS-fentanyl patients    69 
3.3.4 Acceptability of the patches 
 
Corresponding to previous reports, patient acceptance of the transdermal 
application was high (84, 87). The ease of use of the patches, that sometimes have 
been claimed to be less suitable for elderly patients (91), obtained the same level of 
appreciation from the older patients. Approximately 85% of patients rated the 
convenience good to excellent. It was surprising that more than half of the subjects, 
who left the study due to insufficient pain relief, were nevertheless satisfied with 
the use of the patches.  
 
3.4 Conclusion: 
 
From the analysis of this large experience we conclude that, despite great inter-
individual variability in treatment duration and dosage, TTS-fentanyl application 
every 3 days for the treatment of cancer pain is well tolerated and well accepted by 
most patients, including the elderly and opioid naive, at comparable dose regimens. 
 
 
  
 
 
 
 
 
 
Chapter IV: 
 
Opioid tolerance:  
A self limiting phenomenon
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4.1 Patients and Methods 
 
4.1.1 Study design 
  
Chapter IV studies the long-term survivors described in Chapter III. 
 
4.1.2 Statistics 
 
Descriptive statistics were performed regarding the monthly assessments. The TTS-
fentanyl consumption data were normally divided in the first 12 months of follow-
up but were asymmetrically divided for the last 12 months, caused by the much 
smaller number of patients and the greater variability in fentanyl doses. Because the 
number of patients was much larger during the first year compared to the second 
year, the means + standard deviations were measured. The combination of 
symmetrical and asymmetrical data in one plot is known in statistics as the 
phenomenon of heteroscedasticity. Therefore, data corrections have to be 
performed for constructing linear regression curves. The initial mean fentanyl doses 
have to weigh more than the later doses. This is done by multiplying all mean doses 
with 1/√SD. In all the plots, there is an increase in mean fentanyl doses during the 
first 4 months, followed by relatively stable doses during the following months, 
except for 2 periods of 3 months in the patients ≥60 years. For this reason, a linear 
regression curve is constructed for the first 4 months and a second one for the 
remaining months. Statistical calculations for constipation frequency, constipation 
intensity and the use of laxatives were only done if at least 10 patients per 
evaluation point were available. 
 
4.2 Results 
 
4.2.1 Subjects  
 
Forty-five Belgian investigators recruited between June 1994 and 1997 a total of 
663 palliative cancer patients with a wide range of no longer treatable or 
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primarily untreatable malignancies and suffering from moderate to severe cancer 
pain. Data are available from 661 patients with at least 1 TTS-fentanyl 
application. Only 412 (62%) and 210 (32%) patients survived after respectively 
1 and 2 months and 171 patients (25.8%) survived after a treatment period of 
over 13 weeks. Figure 8 shows the number of patients of whom data of drug 
doses and adverse affects are available at the respective follow-up times. About 
75% of the patients died due to tumour progression in the first 3 months after the 
start of the TTS-fentanyl treatment. At the follow-up after 4 months only 162 
patients (24%) survived. 
 
Figure 8: The total number of patients available at each evaluation point in 
function of time (in months: 1= baseline, 2-25 are the numbers for months 1-24). 
 
Figure 9 illustrates clearly that there is a breakpoint during the third - fourth month 
in the histogram that represents the numbers of deaths per month. The number is 
sharply decreasing in the first 3 months and comes further down smoothly in the 
second part.  The possible impact of opioid tolerance was analysed in the patients 
who survived more than 13 weeks (n = 171) patients. Thanks to their favourable 
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survival were these cancer patients ideal candidates to study long-term cancer pain 
treatment with strong opioids. 
 
Figure 9: Number of deaths per monthly interval in function of time. 
 
4.2.2 Demographics and baseline characteristics  
 
Both genders were equally distributed over the study population and the tumor type 
was known for all 169/171 patients: gastro-intestinal 26.4%, breast 25.6%, lung 
8.3%, prostate 6.6% and other 33%. The age groups of <60 years and ≥60 years 
contained respectively 91 (53%) and 80 (47%) patients.  
 
4.2.3 Fentanyl doses 
 
Figure 10 gives the mean fentanyl doses + SD (µg/h.) for the 171 patients 
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months there is a progressive monthly increase from 46 to 135µg/h. Between 5 
and 10 months the doses remained stable between 100 and 150 µg/h.  After 10 
months, the range became somewhat greater and the data were confined between 
50 and 215 µg/h.  Linear regression curves were constructed with F=27.48 in the 
first 4 months. This high F-value indicates that the slope of the curve is steep. 
The very low P-value of 0.0135 indicates that there is a highly significant 
relation between the mean values and time. The second part of the linear 
regression curve is decreasing smoothly as is indicated by the low F-value of 
3.68. This second part has only a  P-value of 0.71(not significant). 
The initial steep slope (F= 32.16) is also seen for the patients <60 years with also 
a statistical significant probability (P=0.0109),  followed after month 5 by a very 
smooth linear curve with a F-value of 0.86 and a P-value of 0.3665 (not 
significant)  (Figure 11). 
For the patients ≥60 years, the initial slope is a little bit less steep (F= 14.06) but 
again with a highly significant P-value of 0.0331. The second part of this linear 
regression curve has a larger spread of data (P= 0.0625) due to the wider range 
of the mean doses from 30 to 262 µg/h. The second part of the linear curve has a 
smooth slope with F = 3,94 (Figure 12).  
 
During the first 4 months the mean opioid doses progressively increase over 
time in the 3 curves (Fig. 10-12). The regression curves fit the data very well 
with R² values of 0.9016 for all patients, and 0.9147 and 0.8242 for respectively 
the patients up to 60 years and those from 60 year and over.  There is for these 
months in the 3 curves a significant correlation between the mean doses in 
function of time (P <0.035 for the 3 curves). 
After 4 months the regression curves are negative in all three figures (Figure 10-
12) and the respective R² values were respectively 0.1696 (for all patients), 
0.0482 (for <60 years) and 0.1798 (for ≥60 years patients) which reflects that the 
linear curve does not perfectly fit the data due to the wider range of doses. Here 
significance between dose and time was absent (P >0.05). 
76   Chapter IV 
Figure 10: Mean TTS-fentanyl doses + SD (µg/h.) in function of time (months) for 
all patients. Number of patients and linear regression curves with  F- and P-values 
are shown.  
 
 
Figure 11: Mean TTS-fentanyl doses + SD (µg/h.) in function of time (months) for 
patients <60 years. Number of patients and linear regression curves with F- and P-
values are shown. 
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Figure 12: Mean TTS-fentanyl doses +SD (µg/h.) in function of time (months) for 
patients ≥60 years. Number of evaluated patients per month is represented. Linear 
regression curves with F- and P-values are shown. 
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4.2.4 Rescue Morphine doses 
 
The mean rescue morphine dose varied between 0 and 57 mg/d. and never 
exceeded 60 mg/d., in accordance with the prescriptions of the study protocol. The 
protocol indeed specified that if the rescue morphine dose to keep the pain score 
below 3.5 on a 10-point visual analog scale was 60 mg/d. or higher, then the next 
TTS-fentanyl application was incremented with 25µg/hr. There was no statistical 
difference in rescue morphine dose within the two age groups and the doses 
decreased slowly during the study; during the second year there was not much use 
of rescue morphine medication (Figure 13). This decrease in the use of rescue 
medication started after 6 months for the younger and after 8 months for the elderly 
patients. 
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Figure 13: Mean doses of rescue morphine in mg/d for patients < and ≥60years in 
function of time. 
4.2.5 Pain relief  
 
The mean pain scores were effectively below 3.5 on the 10-point visual analog 
scale. Insufficient pain relief led to TTS-fentanyl treatment discontinuation in 17% 
of the patients and these patients were further treated to the discretion of the 
treating physician. They have mainly chosen for intravenously morphine and 
continuous spinal infusions administration. 
 
4.2.6 Side effects 
 
Constipation was absent in 63-88% of all checks in patients <60 years and in 54 
– 77.8% of checks in the patients ≥60 years (Table 10). Less than 26% of the 
young patients experienced mild to moderate constipation and only 0-7.2 % had 
sometimes severe constipation. In the older group mild and moderate 
constipation were slightly more frequent (from 7.7 to 46%) and less than 5% of 
these elderly patients developed severe constipation (Table 10). The constipation 
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never obliged the treating physician to stop the opioids or prevented the 
investigator to increase the dose of the strong opioids according to the pain 
intensity.  
 
Table 10: Different severity of constipation for patients <60 en ≥60 years during 
long term use of TTS-fentanyl and morphine for breakthrough or incidental pain. 
 
 No constipation Mild 
constipation 
Moderate 
constipation 
Severe 
constipation 
<60 years 63-88% 5-26% 0-14% 0-7.2% 
≥60 years 47-77.8% 12-46% 7.7-25% 0-4.7% 
 
No constipation was more frequent registered in the younger than in the elderly 
patients (Figure 14). 
Figure 14: Percentage of patients (< and ≥60years) without constipation in 
function of time ( months) with a least 10 available patients per point.  
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Figure 15: Percentage of patients (< and >60years) with different severity of 
constipation in function of time with a least 10 available patients per point. 
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Table 11: Linear regression curve fitting and statistical analysis of different 
severity of constipation in patients < and ≥ 60 years  from Figure 15.  
 
 R² Parameter estimate P 
All constipation 0.669 -17.2 <0.0001 
Mild constipation 0.260 -9.99 0.0277 
Moderate constipation 0.656 -12,3 <0.0001 
Severe constipation 0.311 2.65         0.0205 
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In table 11 is the statistical analysis summarized from the data in Figure 15. The 
total group of young patients has 17.2% less constipation than the older patients, 
which is statistically significant (p<0.0001). The high R² mentions that the data  fit 
well on a linear regression curve. The younger patients have 12.3% less moderate 
constipation and this also is highly statistically significant (p<0.0001). For the 
patients with mild and severe constipation do the data fit less well (low R²) 
although there is still statistically significance with 9.99% less mild constipation in 
the younger group. Younger patients have 2.65% more severe constipation 
(P=0.02).  
 
The percentage of patients under and above 60 years using laxatives was not 
different over 12 months (Figure 16). The younger patients used not significantly 
less frequently laxatives (m = 38+7% of the checks) than the elderly patients (m = 
46 +11% of the checks). 
 
Figure 16: Percentage of patients (< 60 and ≥60 years) using laxatives in function 
of time.  
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4.3 Discussion 
 
Many patients, families, nurses and physicians harbour reluctance and fears 
towards opioid tolerance.  This misconception is frequently used to justify the 
postponement of effective cancer pain treatment with opioids as long as 
possible, “to reserve this effective pain treatment for the more difficult terminal 
phase of life”. In the meantime however many patients worldwide suffer from 
easily treatable cancer pain.  A life expectancy of more than three months was 
one of the eligibility criteria for this open label multicenter TTS-fentanyl study.  
However within 3 months already 75.6% patients had died!  Figure 8 
demonstrates that only 24.4 % of cancer patients without antitumoral treatment 
survive more than 3 months. The data strongly support to implement effective 
cancer pain treatment when there is pain.  The last phase of life is already 
present in most of those patients, a fact of which many caregivers are not fully 
aware. These data give raise to the hypothesis that real life expectancy in 
advanced cancer patients is substantially overestimated sometimes by caregivers. 
 
Figure 9 suggests that cancer patients dying within or after 13 weeks of follow-
up constitute two groups with a totally different clinical course. The first group 
consists mainly of patients with fast growing tumours resulting in a short 
survival time while the second group harbours slowly progressing tumours with 
reasonable lifetime left before dying. Most published data and statements about 
opioid tolerance are based on the analysis of opioid consumption in cancer 
patients belonging to the first rapidly dying group. Many other factors than 
opioid tolerance can influence the opioid consumption in this terminal phase of 
life: disturbed gastro-intestinal absorption, changed drug metabolism and 
excretion, interaction with other drugs, anxiety, changed pain threshold, sleep 
disorders, loss of social function, fear of the dying process.  
Moreover, many statements about opioid tolerance are vague, anecdotal or lack 
solid scientific ground.  Some of these statements: “Increases in daily morphine 
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dose in palliative cancer patients, when they occurred, generally developed over 
weeks to months, and a pattern of rapid escalation in morphine dose did not 
occur in the 17 patients treated over a mean time of 32 days” (71).  The “larger” 
studies about “long term” strong opioid consumption assessments consider mean 
treatment periods of 158 days in 51 patients (72). It is impossible to assess from 
such data how important or unimportant the phenomenon of opioid tolerance 
really is in the treatment of cancer pain.  Better data are not available in 
literature (93, 94). 
 
In an attempt to start clarifying this important scientific and clinical problem of 
opioid tolerance, we analysed the opioid consumption data of 171 patients who 
survived at least 13 weeks. This is a very large number of far advanced, but very 
slowly progressing, cancer patients.  No oncological treatment interfered with 
the pain treatment and the long follow-up time (24 months) with very few deaths 
per month minimises the possible influence of all the “end-of life factors” that 
could interfere with opioid tolerance or opioid dose modifications.  
 
Figure 10 demonstrates that, after an initial steep slope during 4 months, there is 
a relatively stable opioid consumption for up to 24 months after starting TTS-
fentanyl. Also for the mean TTS-fentanyl doses in the age groups <60 years and 
≥60 years (Figure 11 and 12) a progressive increase is noted in the first 3- 4 
months. Especially the curve for the younger patients is more flat from month 4 
until 2 years follow-up. The range in fentanyl doses in the elderly population 
becomes wider after month 10. The explanation for this is not evident. Is there a 
less accurate reporting of pain in some elderly with subsequent under dosages, or 
is it caused by the more difficult or even sometimes no longer existing 
communication with elderly persons and subsequently relative over dosages to 
avoid non expressed pain?  
 
84   Chapter IV 
In figures 10-12 do the linear regression curves fit well with the data during the 
first 4 months (p<0.05 and high R²) while this is less the case for the second part 
of the curves due to the larger standard deviations in opioid doses.  
 
The amount of strong opioid doses given in these palliative advanced cancer 
patients is common in clinical practice and fits well with the literature. Donner et 
al. started with mean TTS-fentanyl doses of 69.5 µg/h. and ended up with 
167.7µg/h after a mean treatment period of 158 days (80). In the study of Slaon 
et al. the mean starting dose was 135 mg morphine/day  (~TTS fentanyl 50µg/h) 
and 244 mg morphine per day (~TTS fentanyl 75 µg/h) at study completion after 
only 32 days (95).  
 
The results of this study concerning a large number of patients over 2 years offer 
scientific evidence that opioid tolerance can easily be overcome during 
prolonged pharmacological cancer pain treatment. The hypothesis that tolerance 
plays an important role and that a progressive increase of opioid doses is 
inevitable to maintain an acceptable level of pain relief is invalidated. Attention 
has to be given to the positive linear regression lines of the mean opioid 
dose/time curves during the first four months (Fig. 10-12). These lines fit very 
well the mean opioid doses, reflected  by their high R² values, all above 0.82. 
There is a clear increase in fentanyl doses in time which is most likely caused by 
opioid tolerance in these patients with very slowly progressing tumours. There is 
no evidence that in untreated advanced cancer patients initial fast tumour growth 
would slow down or stop spontaneously after 3 or 4 months. The opioid 
tolerance enhances the mean daily dose of opioids during the first 4 months with 
100 to 200 %. This tolerance effect seems to be limited in quantity but also in 
time. The linear regression lines after month 4 become even negative (Figure 10-
12) with very low R² values between 0.1696, 0.0482 and 0.1798 for respectively 
all patients, the <60 and ≥60 year old patients.  This indicates that there no 
longer is a positive relation between opioid dose and time. These negative 
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regression lines do not indicate that the opioid doses in individual patients were 
decreasing, since in reality the most far advanced cancer patients, mostly the 
high dose opioid consumers, die first during the follow-up time and can cause 
this decrease in mean overall opioid consumption. Patients with a slightly better 
prognosis survived for a longer time. They were low opioid dose consumers 
what is reflected in these negative linear regression curves after month 5.  
 
Decreasing mean opioid doses during follow-up could also be the result of the 
drop-out of patients for reasons of insufficient pain relief or intolerable side 
effects.  Both issues would however happen very early in the treatment and 
would influence the mean opioid dose during the first 4 months.   
 
In function of time there was neither an increase of constipation frequency, nor 
constipation severity, nor an increased use of laxatives. Long term use of strong 
opioids seems to be well tolerated by both young and older patients.  
 
4.4 Conclusion  
 
This study with many patients (n=171) and very long follow-up time (24 
months) offers evidence that opioid tolerance exists and really has an effect on 
the strong opioid doses in cancer pain therapy. Opioid tolerance can be 
responsible for the progressive increase of the mean strong opioid dose by 100 to 
200% during the first 3-4 months of cancer pain treatment. After month 4, there 
is no further mean opioid dose increase shown in this study. Opioid tolerance 
seems to be a process that is limited in dose and in time. There is no reason to 
hypothesise that tolerance will modify the opioid doses again during follow-up 
times after more than 2 years, a follow-up period which is irrelevant in this 
clinical situation of advanced cancer patients but is relevant for patients with 
chronic benign diseases and pain. 
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Constipation is a rare but manageable side effect and therefore can this  never be 
a reason to withhold cancer patients an effective pain therapy. 
 
We conclude that effective pain treatment with strong opioid dosing according to 
the WHO guidelines in relation to the pain intensity is an effective and safe 
procedure. Opioid tolerance exists clinically but seems to be a process of limited 
importance that causes a dose enhancement of 100 to 200% that is only be seen 
during the first 3-4 months of opioid treatment.
 

  
 
 
Chapter V: 
 
Palliative sedation for refractory 
symptoms in terminal palliative cancer 
patients:  
 
Procedure and results in UH Leuven 
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5.1 Definitions 
 
Many publications, most of them retrospective, describe sedation used as one of 
the comfort measures in palliative patients applied in a few up to more than 50% 
of dying patients. “Light” sedation given to control patients with some degree of 
delirium,  anxiety or insomnia is not the subject of this analysis because this does 
not constitute an ethical problem. The consciousness of these patients is only 
slightly modified to help them to continue to live more comfortably. Withholding 
this light sedation is withholding good clinical practice and has to be evaluated 
as unethical. But the definitions of sedation are vague, even the terms of terminal 
and controlled sedation are not well defined and could be interpreted differently. 
Terminal sedation is widely used in the literature but should be avoided because 
it could be interpreted as “sedation with the intention to terminate the patient’s 
life”, and is therefore a misleading term. ‘Controlled sedation’ suggests that the 
sedation be used to control everything, with a tendency to palliative persistency. 
Therefore it is probably better to speak about ‘palliative sedation’ to indicate that 
the sedation is used to palliate a refractory symptom in a patient’s last phase of 
life. Palliative sedation becomes gradually the most used term for the treatment 
of refractory symptoms in terminal palliative patients. We’ll reserve this term in 
this study for those situations where the terminal palliative patient and his 
physician intend to obtain a deep sleep. The sedation is done without hastening 
or causing death, just to relieve suffering from one or more intractable 
symptoms, when all other interventions have failed and the patient is perceived 
to be close to death. The patient can no longer communicate during this sedation 
and this constitutes an intrinsic ethical problem. Many people perceive it as a 
great difficulty to differentiate palliative sedation from (slow) euthanasia.  
 
In many papers the indications for sedation are not well defined and the practical 
procedures are mostly not reported.  Clinical research is necessary to investigate 
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the indications and the effectiveness, and to elucidate the possible role of 
palliative sedation in terminal patients.  
This study will analyse the indications, the procedure and efficacy of palliative 
sedation for refractory symptoms in terminal palliative cancer patients in the 
University Hospitals of Leuven. Our own data will be compared with the 
literature.  
 
5.2 Patients and methods 
 
Palliative terminal cancer patients in the UH of Leuven are informed since 1997 
by the palliative support team that they don’t have to suffer in the terminal phase 
of life.  They have the opportunity to ask for palliative sedation to relieve 
intractable pain or other unbearable symptoms if they remain unresponsive to all 
other interdisciplinary palliative measures. 
From 1997 to 2002 we prospectively registered 26 palliative terminal cancer 
patients suffering from one or more refractory symptoms in which any form of 
oncological or palliative treatment no longer was meaningful and standard 
palliative care had failed to control the symptoms.  
 
The first ten patients (1997 until September 1999) were in-hospital patients for 
whom the mobile hospital-based palliative support team (PST) was consulted. 
The next 16 patients (September 1999 until December 2002) were patients in the 
palliative care unit (PCU) of the hospital. All patients were fully conscious and 
requested themselves to start palliative sedation because they could no longer 
bear the pain or the suffering and were not able to pass the last phase of their life 
comfortably and with dignity.  
 
Midazolam was always used to sedate these patients. It is a benzodiazepine with 
a fast on- and offset, it is water soluble and can be given intravenously, 
subcutaneously and intramuscularly. Midazolam was mostly started in a small 
92   Chapter V 
bolus (7.5-15 mg S.C.), to induce sedation, concomitant with the start of a 
continuous subcutaneous infusion. The continuous dose rate was assessed by the 
clinician based on the personal medical history of the patient, the individual 
patient’s experience with benzodiazepines and the intensity of the refractory 
symptom(s). The midazolam dose rate was titrated so many times a day as was 
necessary to control the intractable symptoms until death.  
With the start of sedation, a close medical follow-up of the patient and support 
for the family and the caring team were initiated to help them to cope with this 
exceptional situation. 
 
Midazolam is the drug of choice to sedate. Because of its rapid on- and offset is 
it an excellent sedative to continuously optimise the dose in function of the 
symptoms and especially to manage intermittently sedated patients. 
 
5.3 Results 
 
The prevalence of refractory symptoms (Figure 17), the demographics of all 
patients, the doses of midazolam and morphine are summarized (Table 12 for the 
PST-patients and Table 13 for the PCU-patients). 
 
Ten PST-patients had 12 intractable symptoms while the 16 PCU-patients had 18 
refractory symptoms. Physical symptoms (n = 4/10) were substantially present in 
the PST group (3 pain and 1 dyspnoea and terminal agony) while they 
represented a minority (n = 2/16) in the PCU-group (1 pain and 1 dyspnoea).  In 
the PST-group existential suffering (n = 4/10) and psychological suffering 
(n=0/10) were less frequent than in the PCU group (respectively n = 9/16 and 
5/16) (Figure 17). 
 
The intractable symptoms came under control within a few minutes for some 
patients, other patients needed one or more extra midazolam administrations or an 
increased injection rate to avoid waking up. Forty-eight hours after the start of 
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sedation, full control of symptoms was reached in 24/26 patients (92%). In one 
patient of the PST-group (37 year old - female) never came the intractable 
symptoms (physical pain and anxiety) under control, even with very high doses of 
morphine and midazolam. 
 
Figure 17: Reasons for palliative sedation in the Palliatieve Support Team(PST) 
and the Palliative Care Unit (PCU)  patients in the University Hospital of Leuven. 
 
The other patient (also of the PST-group; 74 years old female) was started with 
midazolam IV in a phase of extreme restlessness and terminal agony. She died 
less than 1 hour after the start of the midazolam. At that moment, already 90 mg 
of midazolam had been given I.V. without any effect on the symptoms. 
Midazolam can even have contributed to a hastened death in this patient by 
causing respiratory depression (a high dose I.V. in less than 1 hour). Thereafter 
we never have given midazolam I.V. on such a high dose rate and the normal 
used administration route became as a routine S.C. both for bolus and continuous 
infusion.  
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Table 12: Data from all patients who received palliative sedation by the 
palliative support team(PST) between 1997 and September 1999. Age and 
gender (female/male), duration of intermittent and/or permanent sedation are 
shown. The range of doses of midazolam per 12 or 24h .and  the parenteral 
morphine equivalent  doses in mg/d. are given. 
  
P.S.T.  
n = 10 
Intermittent Sedation Permanent Sedation
Age 
F/M 
Duration  
(d.) 
midazolam 
dose  
mg. /12h. 
Commu-
nication 
possible?
Duration 
(d.) 
midazolam 
Dose 
mg./24h. 
 
morphine 
equiv. dose  
mg. /d.  
(S.C/I.V.) 
47 F    5 90 30 
68 F    1 15 60 
59 F    10 15-45 0 
33 F 1 15 Yes 2 30 600 
74 F    <1 90 10 
37 F 7 90-120 Yes 7 150-450 900-3740 
58 F 1 15 Yes 1 60 100 
56 F 18 30 Yes 0 0 0 
57 F    5 30-75 60-500 
35 F    5 15-90 250-2000 
 
Intermittent sedation was done in 9/26 patients for a duration varying from 1 to 
33 days with a median of 5 days and a mean of 9 days. These 9 patients were 
intermittently sedated for a total of 81 days. Three of nine patients asked on the 
second day to switch to permanent sedation, probably because they felt to be in a 
too weak general condition at this point, being of no more than 24 – 48 hours 
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Table 13: Data from all patients who received palliative sedation in the 
palliative care unit between 1October 1999 and 31 December 2002. Age and 
gender, duration of intermittent and/or permanent sedation are shown. The 
range of doses of midazolam and the morphine equivalent dose are given. 
 
P.C.U. 
N=16 
Intermittent Sedation Permanent Sedation 
Age 
F/M 
Duration  
(d.) 
midazolam 
dose  
mg. /12h. 
Commu-
nication 
possible?
Duration 
(d) 
midazolam 
dose  
mg./24h. 
 
morphine 
equivalent. 
dose  
mg. /d.   
(sc/iv) 
71 F    5 30 30-50 
68 M    4 75-90 30 
77 F 33 20-90 Yes 10 330 0 
71 M 5 30 Yes 5 60-135 60 
56 F    2 75 150 
60 M    6 75-180 40 
47 F    1 30-60 10-20 
65 M    3 150-225 300 
46 M 1 35 Yes 1 35-60 300 
57 F    7 90-225 160 
80 M    2 135 0 
70 F    4 90-225 500-530 
69 M    3 90-120 160 
46 F 11 30-45 Yes 1 150 80 
73 F 4 30 Yes 0 0 0 
59 M    4 120 3000 
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away from death. This “second line” permanent sedation varied from 1 to 10 
days with a mean of 3.85 days and median duration of 2 days. Only 2/9 patients 
were intermittently sedated until death for respectively 4 and 18 days. Sixteen of 
the 25 patients asked to start immediately with continuous sedation and this 
varied from <1 day to 10 days with a mean of 4 days and a median duration of 4 
days.  
 
The individually titrated dose of midazolam in the intermittent sedation group 
varied from 15 to 120 mg/12h while the continuous sedation group was treated 
with doses midazolam of minimum 15 and maximum 450mg/24h. (Figure 18).  
 
Figure 18: Individual doses midazolam per patient are shown in function of time 
from the start of the permanent palliative sedation until death for the last 14 
patients sedated at the PCU. 
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Midazolam has to be individually titrated during the first day, thereafter is the 
dose mostly relative stable. The patient with the highest dose (330 mg/d.) in the 
14 permanently sedated patients in Figure 18 was earlier intermittently sedated 
for 33 days with midazolam doses between 30 to 90 mg/12 h. At the moment of 
starting with permanent palliative sedation the midazolam dose was increased to 
240 mg/d. Above this high dose , she needed regular bolus injections of 15 mg 
because there were signs that she was waking up several times a day with the 
risk of presenting again refractory symptoms.  
 
During the palliative sedation, the pain treatment was continued with a wide 
variation in morphine equivalent parenteral daily dose from 0 to 3740 mg. /24h. 
All other medication that was not substantially necessary was stopped  
(cholesterol lowering drugs, benzodiazepines, diuretics, cardiologic drugs, 
vitamins, antihypertensive drugs,…) 
 
In the registration period of this study 10/750 PST-patients (= 0.13%) and 16/511 
PCU- patients (= 3.13 %) were totally sedated for palliative reasons. Between 
September 1999 until 2002 there was a yearly gradually increasing number of 
dying patients on the palliative care unit while the absolute number of patients 
asking for palliative sedation remained stable (Figure 19). The percentage of 
dying patients that asked for palliative sedation decreased over these 4 years 
from 7.5 to 2.4% (Figure 20). 
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Figure 19: Number of sedated palliative patients on the palliative care unit related 
to the number of admitted and dying patients in the PCU. 
 
Figure 20: Percentage of terminal palliative patients who asked for palliative 
sedation to relieve refractory symptoms on the P.C.U. of the U.H. Leuven. 
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5.4 Discussion 
 
5.4.1 Indications for palliative sedation 
 
There is a shift in the indications for palliative sedation in this study over the 5 
years of registration with a decrease of physical intractable symptoms1 (4/10 
=40% to  2/16 =12.5%) but development of more existential and psychological 
suffering2 (4/10 = 40% to 14/16=87.5%).  The PST-group are patients for whom 
the treating team can ask for palliative advice from the hospital based palliative 
support team. The second group is a palliative care unit group of patients that is 
cared for by palliative professionals on a dedicated palliative care unit with in 
general more clinical experience in pain- and symptom control. Also the two 
different treatment era’s (‘97-’99 and ‘99-‘02) can be responsible for a difference 
in palliative expertise and attitudes. Existential (n = 13) and psychological 
suffering (n = 5), anxiety and terminal restlessness (n = 6) combine 72.7% (24/33 
symptoms) of the palliative sedation indications in this study. This is in contrast 
with the data of Fainsinger (99) that in a multicenter study identified mainly 
physical indications (pain, nausea and vomiting, dyspnoea and delirium) for 
palliative sedation. Existential ‘distress’ was only present in 7/397 of his patients 
(<2%). But more than one-third of his patients were not informed about their 
diagnosis and the patients stated that they did not wish to have any further 
information. This reflects cultural differences. In our patients on the PCU the 
diagnosis is disclosed and the patients know that they are in a PCU where cure is 
no longer possible; they are admitted just for care and symptom control, to 
optimize the quality of their ending live. The disclosed truth might have 
contributed to the feeling of hopelessness for several of these patients. 
 
                                                 
1 ( 3 physical pain + 1 dyspnoe & terminal agony to 1 physical pain + 1 dyspnoe & terminal 
agony) 
2 (4 existential suffering  to  9 existential  + 5 psychological suffering) 
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It’s amazing that family distress is an indication for palliative sedation of the 
patient in the Spanish cohort of Fainsinger’s study. Selected palliative care 
experts use sedation at the end of life for pain (20%), anguish (14%), respiratory 
distress (12%), agitation, delirium, confusion, hallucinations (12%), fear, panic, 
anxiety, terror (10%), emotional, psychological, spiritual distress (10%) 
restlessness (10%) seizures, twitching (4%), nausea, vomiting, retching (2%) and 
others (6%) (99). There is still some confusion about the indications. Morita 
describes “terminal sedation for existential distress” in terminally ill cancer 
patients who expressed existential distress by saying, “their lives were 
meaningless”. Although the title suggests that existential distress is the main 
indication for sedation, the target symptoms for sedation were dyspnoea (n= 10), 
agitated delirium (n= 8), pain (n= 1) and psychological distress (n= 1) (97).  
 
In a review 13 published studies on “terminal” sedation have been summarized.   
The reported indications for terminal sedation were: dyspnoea (11/13), pain 
(11/13), delirium (9/13), nausea and/or vomiting (7/13), but psychological 
‘distress’ in only 2 studies. (98). 
It is clear that variable incidences of refractory symptoms still exist in palliative 
cancer patients. Does this reflect differences in palliative skills, different 
measurements, inter-individual variability of assessments or is this influenced by 
cultural and spiritual factors? 
 
5.4.2 Effectiveness of symptom control 
 
In an international multicenter study Fainsinger reported adequate symptom 
control for “uncontrolled symptoms” in between 53 and 89% terminal patients 
(99). We always discuss with our patients and their family the intensity of 
sedation that will be given. All patients choose to progressively increase the dose 
of midazolam until unresponsiveness occurs, to really avoid any prolonged 
suffering. Symptom control was reached in 24/26 patients (=92%) after <48hours 
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and had to be checked continuously for each individual patient by control of 
patient’s reactions after giving external stimuli. The first day of the sedation is 
used to optimise the dose of midazolam in function of symptom relief. The 
patients with intermittent sedation are all able to communicate and to convince 
us that they are satisfied with the intermittent sedation for 1 or more days. 
In only 2 out of 26 patients the intractable symptoms were not controlled. One 
patient died within one hour after the start of sedation without getting any benefit 
from the treatment and the second patient her symptoms were really resistant to 
even very high doses of midazolam (450mg./24h.) and morphine 
(3740mg./24h.). None of these 2 patients became unconsciousness. 
 
There is some debate in the literature regarding the appropriateness of sedation 
for refractory symptoms that are psychological as opposed to physical in origin 
(98). In this study there was no difference in effectiveness since total 
unconsciousness takes away both physical and psychological symptoms. 
 
5.4.3 The duration and type of palliative sedation 
 
The short period of palliative sedation between 1 to 7 days for 92% (24/26) of 
patients is consistent with the 1- 6 days in the literature (99). Only 2/26 of our 
patients were totally and permanently sedated for a maximum of 10 days. 
 
Very few authors mention the possibility of intermittent palliative sedation and 
nobody discloses some personal experience. Nine patients were intermittently 
sedated in our hospital during 82/177 (= 46%) sedation days. The patients and 
their families evaluated these days as useful “life”, as valuable time before death. 
The patient can ask at any moment to switch from intermittent to permanent 
sedation when the personal perception of quality of life decreases.  The 82 “good 
quality of life” days are net benefit for these patients with otherwise unbearable 
symptoms and also of some benefit for their families. These days are an 
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important argument against euthanasia. Intermittent palliative sedation promotes 
life in this selected group of patients while euthanasia would stop life. This 
proves that palliative sedation is not slow euthanasia. It realises symptom 
control, in respect for the wishes and the autonomy of the patient since the 
patient will choose if he/she prefers intermittent or permanent sedation and 
he/she has to decide if and when the intermittent sedation has to been changed to 
permanent sedation. 
 
5.4.4 Frequency of palliative sedation 
 
Palliative sedation is rarely indicated (0.13%) in a hospital population served by 
a palliative support team, but the indication is more frequently (3.13%) seen in a 
palliative care unit with more complex clinical and psychological problems and 
patients who are not (longer) or less supported by a social or family network of 
palliative care. 
The decreasing percentage of palliative sedation in the PCU can be explained by 
the progressively more skilled and experienced palliative team with consequently 
fewer refractory symptoms. Secondly, the very transparent interdisciplinary 
procedure, that was developed to manage the indications for palliative sedation, 
results in unambiguously clear information to patients and their families by both 
professional caregivers and volunteers. The well-informed patient develops less 
terminal anxiety, less distress and is more confident in the dying process while 
maintaining his/her autonomy. In this situation patients less frequently request 
palliative sedation. Extrapolation from literature or other clinical practices has to 
be done with caution because also in palliative sedation there seemingly is a 
clear learning process to handle new treatments and protocols. There still is, and 
most likely will remain, a great variation in clinical practice, in skills, 
knowledge, attitudes, interdisciplinarity, cultural and psychosocial attitudes 
between services and countries concerning palliative care settings. It is possible 
that some patients with refractory symptoms maybe will choose for euthanasia 
above palliative sedation in countries where euthanasia is legalized. 
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5.4.5 Medications used for palliative sedation 
 
Midazolam is the drug of choice for inducing palliative sedation. In the cited 
palliative expert study, all respondents from the UK (n=20) and three-quarters of 
Canadian respondents (n=19) used midazolam as the primary drug to induce 
sedation (96). 
In our study midazolam was the only drug used to sedate with doses varying 
from 15 to 120 mg/12h. for intermittent palliative sedation and from 15 to 450 
mg/24h. for continuous palliative sedation. This wide range of doses proves that 
a simple kitchen recipe for palliative sedation does not exist but that drug dose 
has to be adapted to the individual patient’s needs. 
 
Although cancer patients seem to develop some tolerance to painkillers over the 
first 2-4 months, there is no suggestion in figure 18 that there is some tolerance 
to midazolam during the palliative sedation. 
 
5.4.6 Ethical considerations 
 
Some authors defend the use of palliative sedation at the end of life with the rule 
of double effect. But the same rule causes reluctance for many physicians to use 
sufficient doses of opioid analgesics, even when their patients are dying, in part 
because of fear (both ethical and legal) of contributing to an earlier death (100). 
The rule of double effect makes it ethically possible to use sufficient doses of 
morphine to control cancer pain; it can however also be used when pain 
erroneously is considered as refractory. The rule of double effect fails to take the 
patient’s wishes into account and this makes its use problematic in many 
circumstances at the end of life (101).  
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There are 4 key conditions for the rule of double effect: 
- The nature of the act must be good 
- The good effect must be intended and not the evil effect 
- Distinction between means and effect; the bad effect must not be a means to 
the good effect 
- The proportionality between the good and the bad effect: the good effect must 
outweigh the bad effect. 
Thus one should choose the action with the most favourable balance between 
good and bad effects, within the limits set by the first three conditions.  In 
palliative sedation there is the bad effect of the unconscious state that deprives 
the patient of further communication. Palliative sedation does not intend and will 
not result in shortening life when midazolam is given cautiously by an 
experienced team. These patients will always die within days (about 90% will 
within a week) due to disease progression. Our multidisciplinary team perceived 
it as unethical to let patients suffer during their last days of life while they ask for 
help. This help can be given in a feasible and effective way by intermittent or 
permanent palliative sedation.  
 
Palliative sedation remains controversial; some view it as “slow euthanasia” 
(102) because the patient not only is sedated to the point of unconsciousness but 
will also be deprived of nutrition and fluids (103). An important consideration is 
that death can never be caused within a few days just by withholding fluid or 
food. The majority of our patients however had already stopped eating for some 
days or even weeks before the start of the palliative sedation. Some patients 
stopped ingestion due to the inability to swallow caused by tumour progression 
others voluntarily stopped eating to avoid futile life prolongation. Those who did 
not yet stop eating before palliative sedation ask to be no longer fed during 
palliative sedation or not to receive treatments that can prolong their life. The 
opposite question has to be asked: is it ethically justified to try to prolong the life 
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of these patients by administering fluids and foods, while the patient would 
suffer without palliative sedation?  
 
Some authors don’t see any difference between slow euthanasia and palliative 
sedation because the result is the same in their mind. Both interventions have the 
aim to stop suffering and both end by death. Morita showed in a prospective 
study that there is no statistical difference in survival rate in palliative patients 
who did or did not receive strong sedatives (104). So there is no justification to 
believe that midazolam shortens life. Palliative sedation is the ultimate tool to 
relieve otherwise intractable suffering. This tool can be used worldwide and 
doesn’t need any change of the laws, as is necessary for euthanasia.  
 
Palliative sedation can ethically be justified by the principle of proportionality. 
Sedation is an exceptional treatment for an otherwise intractable symptom. The 
only alternative for relief of the suffering of these terminal palliative patients is 
euthanasia or suicide. In our practice, the treating physicians and all patients, 
except one, preferred palliative sedation to euthanasia.  
 
Ganzini et al. (105) found that hopelessness but not depression was associated 
with a willingness to consider assisted suicide in amyotrophic lateral sclerosis 
patients. For in-patients with psychiatric disorders, hopelessness is a better 
predictor of suicidal intent and actual suicide than depression (106). The 
existential and psychological suffering in these palliative patients can be caused 
by the hopelessness that is experienced by some terminal patients. This study 
shows that when physical symptoms are better controlled, more existential and 
psychological issues will arise. This is a new and continuing challenge for 
caregivers and all palliative teams; they have to be conscious and aware of the 
changing patterns of symptoms in their patients. 
In an era of legalisation of euthanasia in the Netherlands and Belgium, some 
patients, family members and some caregivers view euthanasia as a right that can 
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be obtained on demand. It recently became by law one of the options that can be 
freely considered by terminally ill patients with extreme suffering. Physicians 
and palliative caregivers should not encourage patients to hasten death, even 
when practising in a jurisdiction that allows euthanasia or assisted dying. They 
should clarify the request, explore and address the patient’s concern, achieve a 
shared understanding of the goals of treatment, search for less harmful 
alternatives, express to the patient what they are willing to do, discuss the 
relevant legal issues, and share their decision-making with competent colleagues 
(107). It is important to remember that physical and mental suffering justifies 
euthanasia in the Netherlands but the public prosecutor recently established 
jurisprudence.  A general practitioner was guilty of helping an 86-year old man 
with no serious physical or mental illness to commit suicide for “existential pain” 
or “being tired of life “. Existential pain is not a justification for euthanasia or 
physician assisted suicide.  
 
5.5 Conclusion  
 
Palliative sedation can be a valuable alternative to euthanasia or physician 
assisted suicide for many terminal patients with intractable symptoms. It is an 
effective (92%) but exceptional (about 0.13% in the hospital and about 3% of all 
dying persons in the palliative care unit) treatment for the rare intractable 
symptoms at the end of life.  
Most authors reported about refractory physical symptoms as indications for 
palliative sedation but this study shows a shift to more existential and 
psychological indications over the years.  The practical implementation of 
palliative sedation for the individual patient can only be formulated following an 
interdisciplinary consultation with respect for the wishes and the autonomy of 
the patient and his family. 
Intermittent sedation was able “to add life to the days but does not add days to 
life” in the ending lifetime of patients who choose for this type of sedation. In 
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deeply sedated patients there is no shortening of life compared to less deeply 
sedated patients, according to the literature. It is obvious that disease progression 
causes death or that the withholding or the withdrawal of food and fluids (mostly 
already chosen by the patient some days or even weeks before the start of the 
palliative sedation ) will stop prolonging the dying process. Sedation has to be 
based on individual drug titration; a simple recipe to define the necessary drug 
dose does not exist.  
 
Palliative sedation is necessary for only a short time (1 to 10 days) before death 
and is ethically justified because the sedation constitutes a balanced response to 
the otherwise unbearable symptoms. 

  
 
 
 
 
 
 
Chapter VI 
Conclusions and perspectives 
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6.1 Emergency hospital admission for pain in palliative 
cancer patients 
 
Pain is a frequent symptom during the home care of advanced cancer patients and is 
in this study responsible for 59% of emergency hospitalizations of palliative 
oncological patients. In the hospital, etiological and symptomatic oncological 
treatment was started for 54% of the patients. This sounds amazing for many 
caregivers since these advanced cancer patients had already stopped anti-tumor 
treatment. Any new serious symptom however needs an open minded approach by 
the appropriate disciplines to balance the advantages and disadvantages of possible 
treatment modalities. When possible a therapy eliminating the cause of the pain is 
the most effective one. In the mean time, an immediate analgesic therapy is required 
to realize symptom relief. When etiological pain treatment is no longer feasible, 
symptomatic treatment is obligatory. Medical decision making in cancer patients is 
a dynamic process until death, since individual disease progression and 
complications usually are unpredictable. This holistic approach requires 
concertation between different disciplines that work interactively and in close 
contact with home caregivers. This is the best guarantee that the patient can be 
appropriately discharged as soon as possible to a home care setting. All persons 
involved have to fulfill the wish of palliative patients to return home. Caregivers at 
home are skilled and experienced in the palliative home care possibilities to enable 
continuity of the hospital initiated care.  
 
In a prospective registration study over 3 months, patients admitted in emergency in 
the department of oncology with pain as sole complaint or one of the complaints 
were rapidly diagnosed, started with therapies that were individually tailored and 
were cared for when necessary until death. This implies that all aspects of 
oncological and palliative therapeutic skills are available as well as a palliative care 
culture. Physicians have to realize that their role progressively decreases but never 
will stop during the patient’s life. During the course of the disease a close 
cooperation with nurses, social workers, dedicated psycho-oncologists and spiritual 
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caregivers gradually develops. Awareness of the progressively changing role of 
caregivers at the end of life is of paramount importance. 
 
Integration of home and hospital care remains a major challenge. This study 
provides evidence for the complementary role that hospital wards can have for the 
many home cared palliative cancer patients who suffer from pain. The study 
suggests that home caregivers and patients have realistic expectations. Patients were 
not dropped off at the emergency department, but were referred mostly with a letter 
formulating the questions or expectations for the future. Few patients entered during 
the weekend but most waited to get advice by their general practitioner on Monday. 
This highlights the important function of the general practitioner as “health care 
manager” for palliative cancer patients. These emergency situations almost never 
are immediately life threatening, but ask for a quick and effective solution. Most 
patients probably did not need emergency hospital admission but could also have 
been helped by an at short notice (within 48 h.) planned hospitalization. Therefore a 
prior consultation and admission planning policy between general practitioner and 
hospital based physician is preferable, to limit emergency hospitalization to those 
patients who really need this and to avoid the burden of emergency admission for 
all parties involved. General practitioners need to have an easy contact with the 
hospital caregivers, by phone or e-mail, for advice and planning. Specialists need a 
facility to admit patients rapidly for observation and treatment.  
 
6.2 Strong opioid use on a long term basis in elderly cancer 
patients 
 
In all palliative care settings pain still is too much present. Since a few decades 
international experts have established validated guidelines stating, that the use of 
strong opioids by mouth, by the three steps W.H.O. ladder and by the clock, is the 
key solution to relief pain for many cancer patients. Morphine myths still survive in 
the mind of many caregivers and patients, frequently precluding an adequate pain 
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therapy because many people try to postpone or even try to avoid the use of strong 
opioids. There is some restraint, especially for elderly people, to start strong opioids 
because of fear of addiction, of development of tolerance, of somnolence, of 
confusion and of respiratory depression. These myths can only be refuted by solid 
clinical research data.  Therefore the use of TTS-fentanyl was studied in 341 
patients over 60 years belonging to a group of 661 TTS-fentanyl treated patients. 
There was effective pain control and the development of opioid tolerance was 
similar for elderly as for all patients. Elderly patients had slightly more constipation 
but there was no increased use of laxatives in the elderly; all the other side effects 
were comparable with those of the other patients. Confusion in the elderly is feared,  
but was only present in less than 5%.  
 
The appreciation and convenience of the TTS-fentanyl patch were good to excellent 
also for the patients above 60 years.  The secret for this good tolerability is that the 
opioids were given in individually tailored doses according to the international 
guidelines. Side effects are slightly more frequently seen, especially in the frail 
elderly persons, when the morphine dose is increased too rapidly or not increased 
adjusted according to pain intensity. The aged persons (>70years) used somewhat 
less TTS-fentanyl, maybe because these patients did not report their pain intensity 
as effectively as the younger persons did or because caregivers were hesitating to 
increase the opioid dose. These study results suggest that all ages of patients can 
tolerate an effective pain treatment with strong opioids. Age no longer is a reason to 
exclude patients from pain treatment.  
 
We strongly advocate that knowledge, skills and attitudes of effective cancer pain 
relief are part of the basic education of both physicians and nurses. It’s the aim that 
all physicians and nurses can handle cancer pain more effectively in the near future 
just by implementing the now available knowledge and using the existing 
guidelines; they really need guidelines for the daily clinical use of pain 
measurement tools, pain control standards and follow up procedures. Pain 
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management has to be an institutional priority and research has to be done also in 
terminal cancer patients to develop more appropriate clinical guidelines. 
 
6.3 Opioid tolerance: a self-limiting phenomenon  
 
Many patients, families, nurses and physicians postpone effective pain treatment 
with opioids to the final part of the end of life, “to reserve this effective pain 
treatment for the difficult terminal phase of life”.  They fear to be powerless against 
the problems of pain and symptom control in the dying process, if opioid tolerance 
indeed would develop. Many expert palliative authors and pain specialists have 
declared that tolerance is not that important and that opioid tolerance cannot justify 
withholding effective pain relief in suffering patients. In the meantime many 
patients suffer worldwide from cancer pain that easily could be treated.  Scientific 
data that invalidate the clinical importance of opioid tolerance are lacking.  
 
For the analysis in chapter IV we selected the long (>13 weeks) surviving advanced 
cancer patients who used TTS-fentanyl as maintenance treatment and an ‘as 
needed’ dose of morphine as rescue medication  for incidental or breakthrough pain. 
By selecting long-term survivors the effect of tumor growth on opioid consumption 
is minimized, allowing to estimate the development of opioid tolerance. The 
sometimes enhanced analgesic consumption pre-mortem cannot be distinguished 
from opioid tolerance in this study. Our data do not indicate the development of 
opioid tolerance after 4 months until 2-years of follow-up. During the first 4 months 
the mean opioid dose progressively increases over time and this probably reflects 
real opioid tolerance. The results of this study offer scientific evidence that some 
opioid tolerance develops during the first 4 months. This is a clinically negligible 
long-term issue in cancer pain treatment. Opioid tolerance does not induce an 
exponential long-term increase of the opioid dose and yet an acceptable level of 
pain relief is maintained. Tolerance development seems to be limited both in 
quantity (increase of the daily opioid dose to about 150 µg/h TTS-fentanyl) and in 
time (3-4 months). 
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The required doses increase progressively during the 4 first months; these data seem 
valid because of the large number of patients. The other end of the curve is less sure 
because the deaths are spread over 21 months. It could be interesting to study the 
fentanyl consumption during the last few months of life, as consumption may be 
less stable at that time. Having eliminated both the first non-stable part of 4 months 
and the pre-mortem non-stable part when present, the middle part can definitely 
answer to what extent tolerance increases beyond 4 months, excluding the issues of 
fast tumor growth or the dying process. It would be very interesting if this analysis 
could be done in the future. Further would it be valuable if somebody else could 
confirm these data concerning the opioid tolerance in cancer pain management. 
 
6.4 Indications for palliative sedation 
 
There is overwhelming evidence in the literature that the existing knowledge of 
pain pathophysiology and the different analgesics used according to the existing 
WHO guidelines can relieve more than 90% of the cancer pain, bringing the VAS 
pain score below 3.5. Occasionally, cancer pain is refractory to analgesic therapies. 
For already 6 years we have used the option of palliative sedation for these patients. 
This was only done at the explicit request of the suffering, well-informed and 
conscious palliative terminal patient. A shift in the indications for palliative 
sedation is seen over 6 years of registration; physical intractable symptoms are 
decreasing (4/10 = 40% (PST) to 2/16 = 12.5% (PCU)) and existential or 
psychological refractory suffering is increasing as indication (4/10 = 40% (PST) to 
14/16 = 87.5% (PCU)).  The PST-group are ward patients for whom the treating 
team was advised by the palliative support team, while the palliative care unit 
patients (PCU) are cared for by palliative professionals more experienced in pain 
and symptom control. The two different treatment era’s ‘97-’99 (PST) and ‘99-’02 
(PCU) may reflect an evolution in palliative knowledge and attitudes. Existential 
and psychological suffering, anxiety and terminal distress constitute 72.7% of the 
indications for palliative sedation in this study. Does this mean that the truth is 
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unbearable for some patients and that the disclosure of the diagnosis and prognosis 
creates existential suffering? We may also suggest that physical pain currently is the 
best amenable symptom in cancer patients; if this symptom is relieved, the patient 
starts reflecting on the story of his life and can end up with anxiety, distress, 
depression and/or existential suffering. All these symptoms are less amenable to 
treatment than physical pain. Even with more social workers, more psychologists 
and more chaplains, some amount of intractable non-physical suffering will always 
be left. It will be more difficult to make the same progress in the treatment of non-
physical suffering as there was in physical pain. Some persons in the Netherlands 
and Belgium think that this problem can be solved by the principle of absolute 
autonomy and an euthanasia law. In the Netherlands, in Oregon (US) and parts of 
Australia physician assisted suicide has become legalized. Will this be the way to 
solve the problems in the near future?  Do we have to provide such escape routes 
for patients with intractable symptoms?  
 
 Or should we return to the first principles of palliative care when ‘love and tender 
care’ were the strongest weapons in an era that physical pain was not so treatable as 
nowadays? In our opinion, one should combine this soft option with correct 
scientific physical care, implementing the efficacy of modern medicine, with 
adequate communication and interaction focusing on both the patient and the 
family. With this holistic approach to the palliative patient, combined with a 
growing palliative experience, the frequency of refractory suffering or hopelessness 
asking for palliative sedation, decreased from 7.5 to 2.4 % in our palliative care unit 
over 4 years. The dying process is dignified by focusing attention on the patient and 
his family, by listening to them, allowing them to fulfill “their good death” while 
the caregivers are witnesses, ready to help and to correct where necessary. 
 
Healthy caregivers and politicians do not have the right to judge patients’ dignity 
(108). Studies show that 93% of patients selves in palliative care units did not report 
significant loss of dignity. Only 7% reported moderate or severe loss of dignity. 
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Death and dying are not inherently undignified for patients, as sometimes perceived 
by healthy persons. There is a danger that loss of dignity may be overstated, 
extrapolated from a few unrepresentative cases that should have become obsolete. 
Research shows that not pain but depression is associated with a desire for 
euthanasia or physician-assisted suicide (109). These results illustrate that common 
perceptions about the dying process are often wrong and misguided. These 
misperceptions probably arise because good deaths do not raise attention, while a 
few tragic cases reinforce natural fears about dying (108). 
 
Instead of offering death by euthanasia as promoted by some, we have offered some 
intractable patients life to the days by using intermittent sedation; the other patients 
were effectively symptom controlled by continuous sedation and were given the 
opportunity to die symptom free, surrounded by their family. Two patients, in the 
early less experienced years, were not relieved from their symptoms by palliative 
sedation.  
 
It is our conviction that palliative sedation is in the majority of the patients by far 
preferable to euthanasia, since the main goal, a dignified and pain free death, the 
best option for both patient and families, is reached in a more satisfying and natural 
way. Research of the dying process, to understand what really matters for the 
patients and how they would like to be cared for, remains a major clinical challenge 
for the next years.  
 
 
 
 
 
 
 

 Summary 
 
Cancer is responsible for 25% of all deaths in the Western world. About 80% of all 
terminal cancer patients suffer from suboptimal pain treatment. However, cancer 
pain can be relieved in more than 80% of the patients. Caregivers have to 
implement the existing knowledge of pain pathophysiology and to follow the 
internationally validated pain treatment guidelines with an individually tailored 
selection of the available analgesics. In the present thesis, 4 questions of effective 
cancer pain treatment in daily clinical practice have been investigated. 
 
Cancer pain is an important human and social issue that was either the only or one 
of the most important symptoms leading to emergency hospitalization in the Leuven 
oncology department for 59% of advanced palliative cancer patients (Chapter II). 
Oncologists made rapid diagnoses, starting individually tailored therapies and cared 
for some patients until death. Such holistic approach requires a judicious balancing 
between all aspects of oncological and palliative therapeutic skills, as well as a 
palliative care culture. Medical decision making remains a dynamic process in 
advanced palliative cancer patients, involving more and more different disciplines 
as new clinical and practical problems develop towards the end of life. Awareness 
of the changing role of different caregivers at this phase of the patient’s life is 
important. A close cooperation between the different hospital based disciplines, in 
close contact with the home caregivers, is the key issue to relieve the total pain of 
the individual patient. 
 
Treatment is more and more limited to pain and symptom control when oncological 
treatments no longer are useful. There is still some reluctance to treat cancer pain 
with heavy medication over long periods of time, especially in the elderly patients. 
Analysis of the strong opioid use in a large group of elderly patients (chapter III) 
confirms that age does not substantially influence the profile of adverse and side 
effects during long-term use of strong opioids. Constipation was slightly more 
120   Summary 
frequent in elderly patients while the incidence of the other adverse effects was 
equal to that of the total group. These results provide evidence that all patients can 
tolerate an effective pain treatment with strong opioids even for long periods of 
time. Age is no longer a reason to exclude terminal patients from effective cancer 
pain treatment.  
 
The myth of development of tolerance to strong opioids already persists for several 
decades while valid scientific data to substantiate this myth in clinical practice are 
lacking. The results of chapter IV in this thesis scientifically validate the clinical 
experience that the development of tolerance to strong opioids is limited both in 
quantity and in time. Opioid tolerance does not induce an exponential long-term 
increase of the opioid dose needed. The phenomenon of a possible drug tolerance 
development was observed during the first 4 months of treatment. After this initial 
time, a relatively stable opioid dose realized an effective pain control until death for 
most patients.  Further research on the chronic consumption of strong opioids by 
cancer patients has to be encouraged. 
 
Cancer pain however cannot always be totally relieved by strong analgesics. All 
aspects of the “total pain” concept can become refractory to standard treatment; this 
is rarely physical pain, but in 75% of the patients this is psychological or spiritual 
suffering, less frequently social suffering. For many of these patients palliative 
sedation was an ultimate but highly effective tool to relieve these “intractable 
symptoms” in our hospital. The difference between “to let die”, while maintaining 
symptom control by palliative sedation, and “to hasten death or to shorten life” by 
euthanasia is highlighted. Ethical considerations are given on this highly 
controversial subject.  
  
A comprehensive approach to cancer pain relief asks for interdisciplinary 
cooperation of skilled medical and paramedical professionals.  It remains a 
challenge to develop better cancer pain relief and control of other palliative 
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symptoms.  The understanding what really matters for patients, how they would like 
to be cared for and the optimalization of the process of dying are other challenges 
for the next few years. Scientifically derived data will have to provide the basis for 
further improving pain and symptom control.
  
 Samenvatting 
 
Kanker is in de Westerse wereld verantwoordelijk voor 25% van alle 
doodsoorzaken. Ongeveer 80% van alle terminale kankerpatiënten lijden pijn door 
onvoldoende behandeling. Deze pijn kan echter behandeld worden in ruim 80% van 
de patiënten. Hulpverleners moeten de bestaande kennis van pijnpathophysiologie 
toepassen in de praktijk. Ze zouden ook de internationaal erkende pijnbeleidslijnen 
moeten gebruiken om tussen de beschikbare pijnstillers te komen tot een 
geïndividualiseerde aanpak. In dit proefschrift worden een viertal aspecten van 
effectieve pijnbehandeling in de dagelijkse praktijk onderzocht.  
 
Kankerpijn is een belangrijk menselijk en maatschappelijk probleem. Alléén  of als 
één van de meest belangrijke symptomen,  is ze oorzaak van opname bij 59% van 
de uitbehandelde kanker patiënten die in urgentie op de oncologie afdeling van de 
Universitaire Ziekenhuizen te Leuven worden opgenomen (Hoofdstuk II). De 
oncologen stellen op korte termijn diagnoses, starten individueel gerichte 
oncologische behandeling en verzorgen sommige patiënten  tot  aan de dood. Deze 
globale benadering vereist een juiste balans tussen oncologische en palliatief 
therapeutische deskundigheid, maar vraagt ook een palliatieve zorgcultuur. De 
medische besluitvorming blijft bij de uitbehandelde palliatieve kankerpatiënt een 
dynamisch proces, waar meer en meer disciplines betrokken worden naarmate 
nieuwe klinische en praktische problemen ontstaan bij het einde van het leven. De 
respectievelijke hulpverleners moeten zich bewust zijn van hun veranderende 
verantwoordelijkheden in deze levensfase van de patiënt. Echte interdisciplinaire 
samenwerking tussen al de ziekenhuishulpverleners, in nauwe samenwerking met 
de thuiszorg, is de sleutel om een goede pijnverlichting te bereiken voor de 
individuele patiënt. 
 
124   Samenvatting 
De behandeling zal progressief zich meer en meer beperken tot pijn- en 
symptoomcontrole, wanneer oncologische behandeling niet langer meer 
aangewezen is. Er is enige terughoudendheid om kankerpijn voldoende assertief te 
behandelen over langere periodes, vooral bij de oudere patiënten. De analyse van 
het gebruik van sterke opioiden in een grote groep oudere patiënten (hoofdstuk III) 
bevestigt, dat leeftijd de tolerantie of het nevenwerkingprofiel tijdens langdurig 
gebruik van sterke opioiden niet beïnvloedt. Oudere patiënten blijken meer frequent 
geconstipeerd te zijn ten opzichte van de totale groep. Deze resultaten tonen aan, 
dat alle patiënten een efficiënte pijnbehandeling met sterke opioiden kunnen 
verdragen, ook over langere tijdsperiodes. De leeftijd kan dus niet meer langer een 
reden zijn om terminale patiënten efficiënte pijnbehandeling te onthouden. 
 
De mythe van het ontwikkelen van gewenning aan sterke opioiden houdt al 
verschillende tientallen jaren stand, hoewel goede wetenschappelijke gegevens 
hieromtrent in de kliniek ontbreken. De resultaten in hoofdstuk IV in deze thesis 
onderbouwen wetenschappelijk de klinische ervaring dat het ontstaan van 
gewenning aan opioiden zowel kwantitatief als in de tijd een beperkt fenomeen is. 
De gewenning aan opioiden doet over langere tijd geen exponentiële stijging in 
dosis ontstaan. Een mogelijke opioidgewenning werd enkel gezien in de eerste 4 
maanden van de behandeling. Na deze aanvangsperiode, kon een verdere stabiele 
dosis opioiden bij de meeste patiënten de pijn controleren tot aan de dood. Verder 
klinisch onderzoek betreffende het chronische gebruik van sterke opiaten bij 
kankerpatiënten moet aangemoedigd worden. 
 
Kankerpijn kan echter niet altijd even effectief behandeld worden met sterke 
opioiden. Alle aspecten van “totale pijn” kunnen weerstandig worden aan de 
standaardbehandelingen. Soms is dit lichamelijk lijden, maar in 75% van de 
patiënten is dit psychisch of spiritueel lijden, zeldzamer sociaal lijden. Voor veel 
van deze patiënten was palliatieve sedatie in ons ziekenhuis het ultieme maar zeer 
efficiënte middel om deze “onbehandelbare symptomen” te controleren. Het 
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onderscheid tussen “laten sterven”, terwijl palliatieve sedatie de symptomen 
controleert, en “de dood bespoedigen of het leven verkorten” met euthanasie wordt 
toegelicht. Ethische beschouwingen worden gegeven over dit hoogst controversieel 
onderwerp. 
 
Een allesomvattende benadering om kankerpijn te verlichten vraagt 
interdisciplinaire samenwerking van vakbekwame medici en paramedici. Het blijft 
een uitdaging om betere controle te krijgen over kankerpijn en andere palliatieve 
symptomen. Leren begrijpen wat de patiënten echt bezig houdt, hoe ze willen 
verzorgd worden en betere begeleiding van het stervensproces zijn andere 
uitdagingen voor de komende jaren. Wetenschappelijke gegevens moeten de basis 
leveren voor verdere verbetering van pijn- en symptoomcontrole. 
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